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Abstract 
The aim of this study was to develop a technique for the surveillance of Multi Drug 
Resistance tuberculosis (TB) in Kwa Zulu Natal. Conventional drug resistance surveys are 
often limited by laboratory capacity to culture Mycobacterium tuberculosis, so the 
development of a high through-put molecular technique for use on clinical samples could 
expand the reach of drug resistance surveillance. Initially allele-specific PCR using either 
linear or hairpin primers was evaluated in a SYBR green based Tm shift assay targeting two 
drug resistance conferring mutations in rpoB and katG. The reproducibility of this assay was 
poor so a real time PCR assay using TaqMan probes was then developed and evaluated. This 
method showed reliable and reproducible results on culture isolates but was found not to be 
sensitive when used on clinical isolates. Further optimization of the method of DNA 
extraction from sputum is required, but the assay has potential to become a rapid surveillance 
technique for both MDR- and XDR-TB. A commercially available Genotype® MTBDRplus 
assay was also evaluated for the surveillance of MDR-TB but was also found to have low 
sensitivity when used on smear negative sputum samples. 
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l .  Introduction
Tuberculosis (TB) is a major health problem in South Africa with annually over 250,000 new 
cases being reported. The estimated annual incidence rate of TB is amongst the highest in the 
world, in excess of 500/ 100 000 population and in some areas the rate exceeds 1,000/ 100,000 
( 1 % ) [ 1-4]. TB is currently one of the leading causes of death in adults and children in South 
Africa. It is predicted that there will be 3.5 million new cases of TB over the next decade in 
SA, and at least 90,000 deaths. A major reason for the escalation of the TB epidemic is the 
evolution of the Human Immunodeficiency Virus (HIV) epidemic [5]. It is estimated that 
approximately 60% of adult TB cases aged 15-49 years are HIV co-infected [6]. The HIV 
epidemic has more than tripled the annual number of new TB cases in South Africa since 
1990 and is continuing to rise. The World Health Organization (WHO) Regional Committee 
for Africa has declared TB to be an emergency in the African region, at its 55th session in 
Maputo, Mozambique, in August 2005. 
Under most circumstances, treatment for TB using the DOTS (directly observed therapy, short 
course) strategy in which a rifampin based four dmg regimen is given under direct 
observation leads to high rates of cure, shortening of the period of infectiousness, and when 
broadly applied, can reduce the incidence of the disease. The effectiveness of the DOTS 
strategy is, however, threatened in areas in which there is a high prevalence of resistance to 
the first-line anti-TB drugs, particularly isoniazid (INH) and rifampicin (RIF), so-called 
multiple drug resistance (MDR) [7]. The development of resistance to these drugs reduces the 
efficacy of standard anti-TB treatment to 77% [8]. This results in lower cure rates leading to 
persistent infectiousness and, thus, greater potential for transmission. The resulting spread of 
Multi-Drug Resistant Tuberculosis (MDR-TB) has potentially devastating consequences. 
Even in a clinical situation where drug susceptibility testing, secondary-line drugs and good 
adherence are present, the disease carries a significant mortality, which can be over 50% in 
HIV co-infected individuals [6]. 
During 1994-2002, the WHO Global Project on Anti TB Drug Resistance Surveillance 
coordinated data collection on more than 250 000 patients' from 109 countries. From the data 
collected, WHO estimated the annual burden of MOR-TB to be approximately 300 000-600 
000 cases and the prevalence of MOR TB to be threefold higher than the annual incidence, 
mainly in low and middle-income countries [9] . However these figures are based on surveys 
conducted in a limited number of countries. Recently the emergence of XOR-TB or 
extensively drug resistant TB (defined as a MOR strain that also is resistant to any 
fluoroquinolone and at least one of the three following injectable drugs: capreomycin, 
kanamycin, and amikacin) [ I 0, 11] suggests that the spread of drug resistant TB can be rapid. 
Population based surveillance for drug resistance is therefore urgently required to describe the 
magnitude and trends of MOR- and XOR-TB worldwide in order for appropriate action to be 
taken [ I 0, 12]. 
A series of surveys conducted by WHO and the International Union against Tuberculosis and 
Lung Disease has shown that MOR strains of Mycobacterium tuberculosis are widespread 
[ 13]. However the global distribution of MOR strains is not uniform, and only in certain 
countries has MOR rates reached levels above 5% in previously untreated patients. A major 
limitation of these surveys has been the selectivity of the sampling and Africa in particular has 
not been extensively studied. Only five countries from the African continent were included in 
the last WHO Global Project on Anti TB Drug Resistance Surveillance carried out between 
1999 and 2002 [2]. 
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(SSCP PCR) [23]. Many of these techniques require initial isolation of Mycobacterium 
tuberculosis and formal DNA preparations so cannot be used directly on clinical samples. 
Others require cumbersome detection techniques not amenable to high throughput analysis or 
expensive solid phase detection systems. However homogenous or "closed-tube" techniques 
that do not require further processing after addition of the clinical sample are available for 
detecting single nucleotide polymorphisms (SNPs). Furthermore, real-time PCR shows 
sufficient specificity and sensitivity to detect drug-resistant Mycobacterium tuberculosis even 
with sputum samples from TB patients without culture. The aim of this study was to develop 




2.1 Future of MDR-TB 
Multi-Drug Resistant TB represents a very important threat to TB control. As with all TB, 
99% of MDR-TB occurs in high-burden resource-poor countries. However, factors such as a 
continuing rise in the size of the world population and population mobility will mean an 
increase in MDR-TB in developed countries as well. It is therefore quite clear that without 
both political backing and sufficient financing, the number of MDR-TB cases in all countries, 
whether already developed or still developing countries, will continue to rise [24 ]. 
Another very important threat discovered through molecular epidemiology in the past decade 
is that some Mycobacterium tuberculosis strains are spreading more quickly than others and 
therefore create problems irrespective of how effective the TB control program is [25]. 
In theory, a solution to this problem seems simple enough. By curing new TB cases (the 
majority of which are susceptible strains), with short course chemotherapy (SCC), through the 
implementation of the DOTS strategy will prevent such cases from becoming resistant and 
multi-drug resistant. Also, since MDR TB cases respond poorly to SCC, a careful introduction 
and close monitoring of second-line drugs to treat these cases will prevent the further 
transmission of these strains [26]. 
Although MDR-TB requires prolonged treatment with more costly and less effective agents, 
some have suggested that in the long run, MDR strains may not be able to replace drug­
susceptible strains unless a major resistant 'super-bug' arises globally [26, 27] [9]. Others 
have contested that MDR-TB strains are less "fit" that drug susceptible strains [23, 24]. 
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However, MOR-TB still remains a serious threat to TB control programs. The elevated levels 
of MOR-TB in certain settings and the high estimates of MOR-TB in some of the TB high­
burden countries should not and cannot be ignored. Some form of action needs to be taken by 
the international community to prevent a global MOR TB problem. These include: 1) 
improvement of surveillance to gather data that will give a better representation of the 
magnitude of the problem and predict how MOR-TB strains may spread in the future; 2) 
follow-up and better understanding through further studies of the fitness of resistant strains 
and 3) expansion/strengthening of TB control efforts (26). So, although genotypic testing 
cannot totally replace phenotypic methods for the detection of antibiotic resistance, a 
molecular screen capable of use on primary clinical samples to detect most mutations 
associated with resistance could be invaluable [28). Thus, there is a need to develop a 
surveillance technique that is not time consuming, cheap and applicable in low-technology 
environments [29]. 
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2.2 Drug Resistance Surveillance in KwaZulu-Natal 
Renewed surveillance of multi-drug resistance is urgently required in KwaZulu-Natal. South 
Africa was included in the last WHO survey of multi-drug resistance, as a result of a 
nationwide project carried out by the South African Medical Research Council. This was a 
population-based, cross sectional study conducted according to WHO protocols. 1n KwaZulu
Natal province 595 drug susceptibility tests were available from patients with no history of 
prior treatment, recruited in 9 different centers. Of these, only 1.7% was found to be MDR 
and low rates were also found in the other South African provinces. However in the last 3 
years since the study was carried out there is mounting evidence to suggest there has been a 
significant deterioration of the situation. The number of MOR cases treated at the regional 
referral centre in Durban (IGng George V Hospital) has increased from 202 in the year 2000 
to over 3000 in the year 2007, and is continuing to rise. 
More recent data have revealed shocking facts with regard to both MOR-TB and XOR-TB. A 
study was carried out to assess the burden of XOR-TB and MOR-TB in a rural area of 
KwaZulu Natal [ 11 ]. The study was carried out from January 2005 - March 2006 and sputum 
samples from 1539 patients were analyzed. MOR-TB was detected in 221 patients. Of these 
patients, 53 had XOR-TB. All 44 patients with XOR-TB that had been tested for HIV were 
found to be HIV positive. There have been many hypotheses with regard to the origin of the 
spread of XOR-TB. One of them was thought to be as a result of the default of treatment of 
MOR-TB. However, this study showed that 55% of these patients had never been previously 
treated for TB. Another interesting factor to note was that these 53 patients had no known 
contact with each other and did not live in close proximity of each other. The only common 
factor was that 67% of these patients had received treatment from the same hospital. This 
study thus revealed that the prevalence of both MOR-TB and XOR-TB was significantly 
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higher that previously thought [ 12]. Furthermore, the similarity amongst the strains as shown 
by genotyping data shows that these strains are being very easily transmitted from one 
individual to the next. It is thus very likely that the transmission of XOR-TB occurred 
nosocomially. This study was therefore found to be very useful in enforcing the seriousness of 
the problem of the drug resistant forms of TB in a resource limited area that also has a high 
prevalence of HIV [ 11]. However, there is still a need to assess the distribution of these forms 
of TB within the province. 
It is critical to determine whether multi-drug resistance is generalized throughout Kwa Zulu 
Natal, or restricted to certain facilities as well as to determine the risk factors for transmission 
of MOR TB [30] so that the appropriate interventions can be more efficiently targeted. There 
are now over 90,000 reported cases of TB in the province making a conventional DST 
difficult to conduct. The development of a novel technique to rapidly estimate levels of multi­
drug resistance in large populations would therefore be of great benefit to health care in 
KwaZulu Natal Province as well as South Africa in general as early detection of drug 
resistance in TB allows starting of an appropriate treatment, which has an impact in the better 
control of the disease [31]. 
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2.3b Cell Wall Structure 
Although it has been difficult to correctly describe the exact constituents of the cell envelope 
of mycobacteria due to difficulties in conventional electron microscopy [35], it is known that 
the cell wall structure of the Mycobacterium tuberculosis is unique among prokaryotes and it 
is a major determinant for virulence for the bacterium [34]. The study by Zuber B. et al. 
(2008) has been a breakthrough since the group has been able to show the different layers of 
the mycobacterial cell envelope including for the first time, an outer membrane, similar to that 
found in gram negative bacteria. It has been found that the cell envelopes of mycobacteria are 
composed of a plasma membrane, an inner wall zone, a medial wall zone and an outer 
membrane. The importance of mycolic acids have once again been re-emphasized for the 
survival of the mycobacterial species. 
Mycolic acids are unique alpha-branched lipids found in the cell wall of mycobacteria. They 
are strong hydrophobic molecules that form a lipid shell around the organism and affect 
permeability properties at the cell surface. These acids may also be a significant determinant 
of virulence in Mycobacterium tuberculosis. They also protect extracellular bacteria from 
complement deposition in serum and are also thought to protect the mycobacteria from 
cationic proteins, lysosyme and oxygen radicals in the phagocytic granules [34 ]. 
There is also a high concentration of lipids in the cell wall of Mycobacterium tuberculosis 
that has been associated with the following properties of the bacterium: impermeability of 
stains and dyes, resistance to many antibiotics, resistance to killing by acidic and alkaline 
compounds, resistance to osmotic lysis via complement deposition and resistance to lethal 
oxidations and survival of macrophages [34]. 
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2.3c Virulence Mechanisms and Virulence Factors 
A number of structural and physiological properties of the bacterium contribute to bacterial 
virulence and the pathology of TB. These include: 
a) Special mechanisms for cell entry. The tubercle bacillus can bind directly to mannose
receptors on macrophages via the cell wall-associated mannosylated glcolipid, mycobacteria
specific lipoglycan lipoarabinomannan (LAM) or indirectly via certain complement receptors 
or Fe receptors. The bacteria is also capable of entering dendritic cells (DC) after binding with 
the lectin DC specific intercellular adhesion molecule-3 grabbing nonintegrin (DC-SIGN) 
[36] 
b) Mycobacterium tuberculosis can grow intracellularly, which is an effective means of
evading the immune system. Once Mycobacterium tuberculosis is phagocytosed, it can inhibit 
phagosome-lysosome fusion. The exact mechanism used by Mycobacterium tuberculosis to 
accomplish this is not known but it is thought to be the result of a complex interaction 
between bacterial proteins and the phagosome. The bacterium may then remain in or escape 
from the phagosome. 
c) Mycobacterium tuberculosis possesses specific mechanisms to protect against the toxic
effects of reactive oxygen and nitrogen intermediates, such as katG. 
2.3d The Genome of Mycobacterium tuberculosis 
Mycobacterium tuberculosis contains a single chromosome. The genome is very much like 
other eubacterial species in terms of its structure and organization. Mycobacterium 
tuberculosis has a sequence consisting of 4, 411, 529 base pairs (bp) and a GC content of 
65.6%. It has also been found that that the GC content was relatively constant throughout the 
genome [34, 37]. 
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2.4 Multi drug resistance of Mycobacterium tuberculosis 
In 1943, Selman Waksman and his colleagues discovered streptomycin. This discovery was 
important since it provided a chemotherapeutical approach to TB treatment. However, soon 
after the initiation of this chemotherapy era, it was found that not all cases of TB could be 
treated with streptomycin due to the emergence of resistant strains of TB [34]. The potential 
impact of drug resistance in the treatment of TB thus became apparent [38]. In the following 
years, other drugs were discovered including isoniazid, pyrazinamide, ethambutol and 
rifampicin. Although it was shown that administering these drugs simultaneously could 
prevent the emergence of resistant mutants as the rate of spontaneous mutations against two or 
more drugs is very low [34, 38], inadequate treatment and other factors can lead to the 
emergence of resistance to all of these drugs. 
Multi-drug resistant TB is the result of the stepwise accumulation of chromosomal mutations 
and is not due to a single event such as the acquisition of a plasmid or transposon [39]. 
Possible reasons for the acquisition of mutations include inefficient prescription and follow-up 
of chemotherapy by the clinician, poor compliance, or the administration of an in 
inappropriate treatment regimen [5, 40, 41]. The use of anti-TB drugs of inferior quality is 
another confounder, as is the sale of these medications over the counter and on the black 
market [ 13]. 
Rifampicin resistance conferring mutations occur spontaneously at an estimated rate of I in 
10
8 
bacilli, while isoniazid resistance arises in approximately l in 10
6 
bacilli [38, 42]. Due to
selective pressure, the susceptible bacteria are slowly eliminated while the resistant bacteria, 
that have an obvious advantage, begin to dominate the population giving rise to "acquired 
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resistance" [ 43]. Transmission of these drug-resistant Mycobacterium tuberculosis strains 
leads to new TB cases or 'primary resistance' (defined as the development of active TB after 
infection with resistant strains) which eventually led to the emergence of multi drug resistance 
[38]. 
Thus, as postulated many years ago, it appears as though random mutations conferring 
resistance occur naturally during microbial replication and are then selected by incorrect drug 
use [34, 39]. 
Although, it is reassuring that multidrug resistance does not occur through a new resistance 
mechanism, it is imperative that suitable measures are taken to effectively contain the spread 
of MOR-TB. To do this, research needs to be carried out on a continual basis, especially in 
two important areas. Firstly, molecular tests that allows for the early detection of resistance, 
thereby allowing more efficient patient treatment and management, needs to be improved and 
evaluated. Secondly, new, improved drugs that are more efficacious and has fewer side effects 
than those currently available must be identified. It is also extremely important to discover 
new compounds that would be active on dormant Mycobacterium tuberculosis. The 
availability of such a compound or compounds would prevent relapse while also playing a 
vital role in eliminating Mycobacteriwn tuberculosis from the huge latently infected 
population in the world. This would, effectively reduce the "size of the potential reservoir" 
[39]. 
In the l 980's, a presumptive diagnosis of TB was usually made on the basis of patient history, 
clinical and radiological findings and on the presence of acid fast bacilli in smears [44]. 
Although, the tuberculin skin test was also available, isolation of the bacterium was required 
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to confirm this diagnosis. Routine culture was found to be the most reliable method. This 
method is, however, highly technical and costly both in terms of time and reagents [44]. Thus, 
in resource poor countries especially, cultures are not readily available [45]. A slightly faster 
method was the examination of direct smears for acid fast bacteria. Another method used was 
direct microscopy but this requires a skilled technician for interpreting the smears and the 
presence of a large number of acid-fast bacteria. The introduction of the BACTEC system 
followed which greatly reduced the time for detection, final identification and susceptibility 
testing for Mycobacterium tuberculosis. However, the drawback of this system is that it 
depends on growth of the bacteria [44]. Non cultural methods for the diagnosis of TB soon 
followed. These include the direct detection of specific nucleotide sequences in clinical 
material by using nucleic acid probes [ 45]. These nucleic acid amplification based genotypic 
assays are extremely sensitive and rapid for the detection of drug resistance and include DNA 
micro arrays and Strand displacement amplification. The advantage that these systems offer is 
that they greatly shorten the time taken from diagnosis to the delivery of effective 
chemotherapy [46, 47]. 
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2.5 Mechanisms of Drug Resistance in Mycobacterium tuberculosis 
2.5a Overview of resistance mechanisms 
Naturally occurring plasmids are not found in clinical isolates of Mycobacterium tuberculosis. 
So although plasmids are known to be the carriers of antibiotic resistance genes in other 
bacteria, they are not thought to play a role in this phenomenon in Mycobacterium 
tuberculosis [34]. 
Although insertion sequences are found in the Mycobacterium tuberculosis genome, there is 
no evidence that is suggestive of their involvement in the transfer of DNA among strains. 
Furthermore, since the bacteria infect and live within the macrophage and do not have a free­
living stage, this minimizes the opportunity for the bacteria to exchange DNA [48]. 
However, mycobacteria display low-levels of resistance to most common antibiotics and 
chemotherapeutic agents which is probably due to the hydrophobic cell envelope, as described 
earlier. Mycobacterium tuberculosis also has other mechanisms that make them naturally 
resistant to drugs such as drug-efflux systems. Therefore, the drugs that can act against these 
bacteria are quite limited [37]. Despite this fact, effective chemotherapy for TB was derived in 
the 1960s. 
Mycobacterium tuberculosis displays three major mechanisms of resistance to antimicrobial 
agents. These are: altered cell wall permeability or drug efflux, drug titration due to target 
overproduction and alteration of the target by mutation. The fourth mechanism of resistance, 
inactivation of the drug, is not a method that is currently thought to occur in Mycobacterium 
tuberculosis as no enzymes that are capable of doing this has been found in this pathogen [39] 
Resistance can also occur as a result of loss of activation of pro drugs such as isoniazid. The 
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most common resistance mechanism is alteration of the target. This causes a decrease in drug 
binding and occurs as a result of mutations in chromosomal genes. This technique is 
employed by these bacteria both in the case of anti-TB drugs isoniazid, and ethionamide as 
well as in resistance to the broad spectrum antibiotics rifampicin, streptomycin and 
fluoroquinolones. Overproduction of the drug target also appears to lead to resistance to 
isoniazid and ethionamide whereas changes in permeability or the activation of antibiotic­
efflux systems, may contribute to the low-level resistance of the tubercle bacillus to 
streptomycin and fluoroquinolones [39]. 
The acquisition of resistance to a specific drug is of no benefit to the bacterium unless it is 
exposed to that drug [ 16]. It is only in the presence of that drug, that the drug susceptible 
bacteria are killed while the mutants that are resistant to the drug survive. If a patient 
undergoes a second course of chemotherapy with another drug and the same scenario occurs, 
it eventually happens that you have bacilli that are resistant to more than one drug. This is the 
predominant mechanism for the development of multi drug resistance, where there is an 
accumulation of chromosomal mutations in individual target genes [ 16]. Multi-drug resistant 
TB is defined as a strain of TB that is resistant to at least isoniazid and rifampicin, the 
backbone of the standard regimen for treating TB [49]. Thus only these two drugs and their 
targets will be discussed in more detail. 
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2.5b Resistance to Isoniazid 
Isonicotinic acid hydrazide, 4- pyridinecarboxylic acid hydrazide [ 16] or isoniazid was 
synthesized for the first time in 1912 by two Czech biochemists [34]. However, it was only in 
1951 that its anti-TB activity became known. Since isoniazid was further proved to be a 
powerful anti-TB agent with relative efficacy and low toxicity, its discovery was a huge 
advancement in the chemotherapy of TB [39, 50]. In terms of its structure, isoniazid has a 
very simple chemical structure consisting of a hydrazide group attached to a pyridine ring 
[51 ]. 
Isoniazid enters the tubercle bacillus by passive diffusion and has been found to be a very 
effective bactericidal agent since it inhibits fatty acid metabolism as well as nucleic acid and 
protein synthesis [39, 51, 52]. However, it is a prodrug that needs to be converted to an active 
form before exerting a toxic effect on the bacillus [53]. The enzyme responsible for this 
activation is katG, a 2223-bp gene encoding an 80-k.Da hemoprotein of 744 amino acids that 
has a catalase-peroxidase (a heme-containing enzyme) [53, 54]. katG oxidizes isoniazid which 
transforms the drug into a nucleophilic radical. This radical then reacts with the co-factor 
NAD
+ 
thereby yielding a potent inhibitor of the enoyl-ACP reductase InhA. The inhibition of 
lnhA affects the synthesis of mycolic acid, an important component of the bacterial cell wall 
[55]. This results in the loss of acid fastness in the tubercle bacillus [34]. 
The genetic basis of resistance to isoniazid is complex and involves multiple loci. The 
principal mechanism of high level resistance is due to mutations in katG [54]. Although katG 
insertions and frameshifts do occur and induce complete loss of the functional gene product, 
most mutations identified in clinical isolates are single-point mutations [53, 56]. In some 
isoniazid resistant strains that had completely lost their catalase-peroxidase activity, the katG 
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gene had been deleted from the chromosome. However, this phenomenon is quite rare ( ~5% ). 
Most isoniazid resistant strains have missense mutations in the katG gene that affect their 
catalase-peroxidase activity and result in variable levels of resistance (34]. 
These mutations generally affect the catalytic domain (which contains the active site) of 
catalase peroxidase and in some cases change the structure of the active site. These 
substitutions have a negative effect on the activity of the enzyme. Other substitutions that 
affect a glycine rich loop that is close to the substrate diffusion channel of catalase peroxidase 
also leads to a loss of enzyme activity (39]. 
As mentioned previously, mutations in codon 315 of the katG gene are considered to be the 
most prevalent mutations encoding higher levels of resistance to isoniazid [57]. Since this 
mutation is associated with a low fitness cost, easier transmission of such a strain allows 
evolution of this strain to an MOR strain as a result of its maintained fitness. It is interesting to 
note that the distribution of isoniazid resistance-conferring mutations has been reported as 
different in isoniazid-monoresistant isolates from that in multidrug resistant isolates. 
Mutations in katG3 I5 were significantly more common in the multidrug-resistant isolates 
[58]. This evidence thus supports the notion that katG315 mutations have been found to be a 
marker for MOR [57, 59]. 
Although numerous isoniazid resistance conferring mutations in katG have been described 
[ 15, 54), it has been found that the Ser315Thr mutation is the most prevalent mutation 
encoding higher levels of resistance to isoniazid (30% to 90% of resistant strains), depending 
on geographical areas (41, 46, 57, 60-62). A population based survey has also demonstrated 
that amongst katG mutations only this particular mutation is effectively transmitted (7), which 
is compatible with it being the most frequently encountered isoniazid resistance-conferring 
18 
mutation (60% to 100% of surveys) [53, 63]. The Ser315 residue that acts as a heme ligand, 
when replaced by Thr affects both heme-binding and catalysis thus causing severely impaired 
enzyme activity [39]. In a study carried out in the Middle East, 60% of mutations occurring at 
codon 315 of the katG gene were found to be Ser3 l 5Thr mutations [ 64]. A similar result was 
also found in a study carried out in South Africa by Haas W.H. et al. (1997) [60]. An even 
higher percentage of this particular mutation was found in a study carried out in Germany 
which investigated resistance mutations of MDR strains (84.5% of MDR strains) [65]. 
Biochemical evidence obtained from studies involving purified wild type and mutant proteins 
suggest that this mutation results in a competent catalase peroxidase that has a reduction of 
about 50% in its ability to metabolize isoniazid (66, 67]. This mutation also causes a 
significant decrease in the INH mediated inhibition of the activity of the NADH dependent 
enoyl [acylcarrier protein] reductase, InhA, compared to wild type katG in an in vitro assay 
[66]. The high frequency with which variants with this mutation are recovered from patients 
all over the world suggest that Mycobacterium tuberculosis cells achieve a good balance 
between the need to maintain catalase peroxidase activity and the need to reduce the 
conversion to the prodrug isoniazid to its activated form without a significant loss of bacterial 
fitness [68, 69]. There is also laboratory and clinical evidence suggesting that the Ser315Thr 
substitution is a low cost mutation that does not reduce the virulence or transmissibility of the 
bacterial strain [50, 69, 70]. Furthermore, a study carried out by Marti Ila et al. ( 1998) [71], in 
the St. Petersburg area of Russia found that the Ser3 l 5Thr substitutions in the katG gene were 
predominant (92%) among 27 multidrug resistant Mycobacterium tuberculosis isolates. 
Another very interesting point to note is that this mutation was also found to be the most 
prevalent mutation (77 out of 79 isoniazid resistant isolates) in a study carried out in Kwa­
Zulu Natal by Kiepiela P. et al (2000) [61] thus making it a very important mutation to target. 
19 
Other isoniazid resistance conferring mutations also occur. After katG mutations, mutations in 
the promoter region of inhA are the most common. These result in upregulation of inhA, a 
target for activated isoniazid but only confer low level resistance. Other genetic loci 
implicated in isoniazid resistance include kasA, ahpC and ndh [39]. It is conceivable that 
different mutations lead to differences in the degree of resistance and to differences in the 
ability to generate next generation cases [57]. 
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2.5c Resistance to Rifampicin 
Rifampicin (a lipophilic ansamycin) was first isolated from Streptomyces mediterranei in 
1963 and is a broad-spectrum antibiotic [39, 72). It was introduced as an anti-TB agent in 
1972 and since then it has been a crucial drug in short course multi-drug anti-TB therapy [73). 
It is highly active against mycobacteria since it diffuses rapidly across the hydrophobic cell 
envelope [34). Rifampicin is a bactericidal agent and is a potent inhibitor of bacterial DNA
dependant RNA polymerase. It works by binding to the 13 subunit of the polymerase encoded 
by the rpoB gene, which is involved in chain initiation and elongation. This inhibits the 
initiation of transcription [39, 73). 
Rifampicin resistance is particularly amenable to detection by rapid genotypic assays because, 
as 95% to 98% of all rifampicin-resistant strains contain mutations localized in an 81-bp core 
region of the bacterial RNA polymerase gene, rpoB (between bases 1276 and 1356 or codons 
507-533) [ 15, 19, 74, 75]. Mutations that occur in this region confer resistance to rifampicin
and rifampicin susceptible Mycobacterium tuberculosis isolates have the same wild-type 
nucleotide sequence in this region which is highly conserved. Thus, the detection of a 
mutation in the rpoB core region is usually sufficient to state that the bacilli are rifampicin 
resistant [76). It was observed that resistance to rifampicin follows a "single-step, high level" 
resistance pattern in which mutations occur spontaneously at a rate one mutation per 10-
7 to
10-9 organisms [77, 78). Studies carried out on the cost of rifampicin-resistance conferring
mutations to mycobacteria have shown that there are certain mutations such as the Ser53 I Trp 
that confer a high level of resistance but are not commonly isolated from patients since they 
confer a high fitness cost to the bacteria thereby preventing these strains from being easily 
transmitted [79, 80). 
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Most of the mutations in the rpoB gene are rnissense mutations but insertions and small 
deletions also occur. The result of these genetic adaptations is an enzyme that is still 
functional but now represents an altered target for rifampicin. The more common mutations, 
His526Tyr and Ser531Leu, represent more than 70% of the mutations found in clinical 
isolates [39]. Since there is a lot of information available on mutations responsible for 
rifampicin resistance, the development of molecular tests for the rapid detection of rifampicin 
resistance has been made a lot easier [39]. 
Studies carried out have shown that mutations in codon 531 of the rpoB gene are one of the 
most frequently encountered mutations [81]. The detection of specific rpoB alleles in this 
codon can predict high-level resistance and simultaneously provide indirect information about 
susceptibility to other rifamycins [82]. The Ser53 l Leu mutation has also been found to 
account for 54% of rifampin-resistant isolates. The high frequency of this mutation is 
probably due to the low fitness cost associated with this mutation [27]. 
Rifampicin resistance is an excellent marker for MOR-TB because all MDR strains are 
resistant to rifampicin and rifampicin monoresistance is uncommon [ 19, 83, 84]. ln most 
populations 90% of all strains of Mycobacterium tuberculosis that are resistant to rifampicin 
are also resistant to isoniazid [85]. Therefore, it is not necessary for a screening assay to test 
susceptibility to all anti-TB drugs. 
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2.6 Cost of Antibiotic Resistance on the Fitness of Bacteria 
Studies using model systems have shown that, although there is a range, most resistance 
conferring mutations convey some cost to bacteria in terms of their fitness (a composite 
measure of an infectious organism's ability to survive, reproduce, and be transmitted) [56, 79, 
86). The extent of this fitness 'cost' and resultant effect on bacterial virulence [87) is however 
dependent on the specific drug resistance-conferring mutation and the genetic background of 
the strain (7, 26). In some cases, these costs can also be partially compensated for by 
secondary or compensatory mutations that restore levels of fitness towards those of sensitive 
strains (27, 88-90) and this appears to be the case for Mycobacterium tuberculosis. 
Antibiotic resistance 1s commonly associated with a reduced competitive ability against 
antibiotic-sensitive strains in the absence of the relevant antibiotic (27). It is thus thought that 
a reduction in the use of antibiotics will lead to a reduction in the frequency of resistant 
bacteria in the population. The rationale for this idea is that since resistance is associated with 
a reduced bacterial fitness and that in the absence of the drug, susceptible strains will thrive 
and out compete resistant bacteria and as a result the frequency of resistance will decline [79). 
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2.7 Methods for detecting Single Nucleotide Polymorphisms 
Variation at the genomic level consists mostly of sequence differences in single nucleotide 
positions. These differences are commonly referred to as SNPs [9 l]. Single nucleotide 
polymorphism analysis has been found to be very informative with regard to the study of drug 
resistance, evolution and molecular epidemiology not only in Mycobacterium tuberculosis, 
but in other organisms as well [67, 76, 87, 92]. This type of analysis can also play a crucial 
role in confirming associations between specific SNPs and a phenotype of interest, such as 
drug resistance [92]. Another interesting property of SNPs is that they are stably inherited thus 
making them excellent targets for the detection of a phenotype of interest [91]. 
Thus far, various methods have been described to detect SNPs. These methods involve target 
sequence amplification followed by the detection of variations in the DNA sequences by short 
hybridization probes or by restriction enzymes; discrimination uf mismatched DNA substrates 
by polymerases or ligases; or by observing the template dependant choice of nucleotide 
incorporated by a polymerase. These molecular strategies include the following: 
2.7a Assay Hybridization: These are assays which rely on the differences in hybridization 
stability of short oligonucleotides to target sequence variants (either mismatched or perfectly 
matched sequences). The problems with this assay includes the limitations of multiplex PCR 
and oligonucleotide hybridization to complex DNA samples as well as lack of flexibility 
caused by hardwiring of markers on a chip that is not easy to redesign [91]. 
2. 7b Restriction Digestion: If a SNP alters the recognition sequence for a restriction
enzyme, the products produced after a restriction enzyme cleavage will differ in size to those 
obtained when using a native DNA template. When these products are electrophoresed, their 
migration patterns will differ. This is the principle used in the microtiter array diagonal gel 
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electrophoresis technique (MADGE). The problem with this process is that an estimated 50% 
of all SNPs do not alter any restriction enzyme recognition sequence [91 ]. 
2.7c Mismatch Distinction by Polymerases and Ligases: The polymerization reactions in 
PCR require correct base pairing on the 3' end of the hybridizing primers. This is the principle 
used as the basis on the design of Allele-Specific PCR (ASP). But in this method, a DNA 
ligase is used to join two oligonucleotides that are hybridized to a target DNA sequence. 
Mismatches at or near the 3' end of the ligation site can then be detected by either the 
oligonucleotides ligation assay or the ligation chain reaction. The disadvantage of these assays 
is that a lot of optimization is required [91]. 
2.7d Minisequencing: In this method, DNA polymerase is used to add a specific nucleotide 
to a single primer. The nucleotide added is target dependant. This method allows a more 
accurate distinction between variable nucleotides located immediately downstream of the 
primer [91 ]. 
2.7e Pyrosequencing: This method involves the amplification of the gene of interest, 
followed by subjecting the PCR products to Pyrosequencing analysis using sequencmg 
primers 10 overlapping regions. This allows for the detection of mutations in the gene of 
interest through the detection of pyrophosphate release upon incorporation of a nucleotide. 
This technique differs from standard sequencing, in that no fluorochromes or radioactivity is 
used and that no post-reaction step is required. Other advantages include the fact that shorter 
DNA sequences are generated. The technique is also easy to automate and has been 
determined to be accurate in the determination of specific mutations. Since the reaction can be 
carried out in a 96 well format, it allows fast prediction of mutations and can be used for the 
simultaneous screening of a large number of samples. However a potential problem of this 
technique is that looping and self-priming do commonly occur [93]. 
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2.7f Homogenous Hybridisation: Two assays have been developed that allow hybridization 
based allele-discrimination during PCR. These are the TaqMan assay and the Molecular 
Beacon assay. 
The most important point to take into consideration is that the ideal SNP detection method, as 
stated by Hazb6n M.H and Alland D. (2004) [92] should be "simple to design, easy to 
perform under uniform assay conditions, easy to automate and inexpensive". Of the methods 
mentioned above, only the PCRs that can be used for the detection of SNPs will be discussed 
in more detail. 
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2.7g Types of PCR that can also be used for this purpose 
2.7g (i) Allele-Specific PCR 
This method is very similar to real-time PCR (RT-PCR) that relies on fluorescent 
oligonucleotides probes [46, 47, 59, 76, 81, 85]. However the modified oligonucleotides used 
in RT- PCR can be quite expensive. Allele-Specific PCR on the other hand, is an 
uncomplicated and inexpensive method of SNP genotyping that does not rely on these probes 
[94]. 
Allele-specific PCR is dependant on the non detected allele having a mismatch at or near the 
3' nucleotide of the primer which, as can be expected, considerably reduces the efficiency of 
the amplification process [94]. This homogenous melting temperature or Tm-shift genotyping 
method uses two allele-specific primers each of which contains a 3' terminal base that 
corresponds to either the wild-type nucleotide or the expected mutated nucleotide, a reverse 
primer that amplifies both allelic variants and a fluorescent dye that can detect a double
stranded DNA (dsDNA) product, such as SYBR green [94, 95]. Therefore whether just one of 
the primers or both of them amplify the sample is dependent on the sample genotype [95]. 
Usually amplification is more efficient and occurs more quickly with the perfectly 
complementary primer than that which contains the mismatched primer [92]. Since the 
temperature at which primer template duplexes dissociate, depends largely on product length 
and GC content, the PCR product will have a distinct Tm, depending on which one of the two 
primers is responsible for the amplification [96]. By adding GC-rich tails of differing lengths 
to each primer, the difference of the Tm of each PCR product can be altered to be even more 
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distinct. The genotypes can then be determined by the generation of a melting curve on a real­
time PCR instrument [95). 
Optimization of this assay can be done by altering the lengths of the GC tails added to the 
primers or by altering the concentration of primers added to the PCR [95). However, this may 
be a time consuming exercise. Although it is possible for a primer to amplify template DNA 
despite a 3 ' terminal mismatch, the amplification of the non-matching template is usually 
delayed. This can be seen through a comparison of threshold cycle (Ct) values [94). The Ct 
value is the cycle at which there is a significant increase in fluorescence, and this value is 
associated with exponential growth of the PCR product during the log-linear phase [97). 
The advantages of using this assay are that, as mentioned previously, it is a simple and 
inexpensive method and does not rely on modified oligonucleotides probes. In terms of 
material requirements, this system requires just a few materials in addition to what is required 
for standard PCR amplification. Since it is also a high throughput method, a large number of 
samples can be processed in a very short period of time. The assay is also very flexible. It can 
be performed in a single closed tube and requires no post-PCR processing, thereby drastically 
reducing the risk of contamination. Since both alleles are detected in a single reaction, the Tm­
shift assay allows an internal amplification control thereby eliminating the risk of false­
negative results. The Tm shift genotyping method is also a very accurate genotyping method 
[95). 
Allele-specific PCR has been used to distinguish between the wild type and mutated alleles of 
the katG3 I 5 of Mycobacterium tuberculosis. It was found that this multiplex allele-specific 
(MAS-PCR) assay could be performed on both purified DNA preparations as well as DNA 
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samples from crude cell lysates and sputum slide preparations. However, there was a slight 
difference in the method used in this study as restriction enzymes were used to digest the 
amplified katG315 fragment. If a mismatch occurred at this position, an additional restriction 
cleavage site was created. The resultant bands produced by restriction enzyme cleavage would 
then differ from the bands produced by restriction cleavage of a non-mutated allele. These 
products were then viewed on an agarose gel to determine the presence or absence of a 
mutation. This is in contrast to the method of detection of mutations by generating and 
analyzing melting profiles of the ASP described before [ 18]. A similar study was then carried 
out to detect mutations in codons 516, 526 and 531 of the rpoB gene of Mycobacterium 
tuberculosis. The study proved highly useful in detecting rifampicin resistant and hence 
MDR-TB in regions with high burdens of MOR TB [19]. 
The concept of MAS PCR was then taken a step further by developing a MAS-PCR that 
targeted codon 315 of the katG gene, codons 516, 526 and 531 of the rpoB gene, the mabA­
inhA promoter region and codon 306 of the embB gene. This method as compared to culture
based phenotypic drug susceptibility testing showed a sensitivity of 77.3% and a specificity of 
99%. This assay was an improvement to the MAS PCRs described previously as it combines 
three tests in a single assay, thereby increasing the efficiency and decreasing the detection 
cost. This method therefore provides a rapid screening tool for a majority of resistant 
Mycobacterium tuberculosis isolates [98]. However, the one disadvantage of this method is 
that since SYBR green (a non-specific dye) is used for the detection of PCR products, a lot of 
optimization is required before the method can be considered to be reliable. 
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2. 7 g (ii) Detection of SNPs using Hairpin primers
This is an alternative ASP-PCR method that uses hairpin primers. Hairpin primers (so-called 
due to their shape) are modified primers that are used to detect SNPs through the addition of a 
5' tail complementary to the 3' end of the linear primer [92]. Hairpin primers are very similar 
to molecular beacons. The loop sequence is complementary to the target sequence while the 
stem is formed by the annealing of the complementary arm sequences of between 5 - 7 
nucleotides long on the ends of the oligonucleotide. Due to the fluorescent label and the 
quencher chromophore being in such close proximity to each other, little or no fluorescence 
occurs. During hybridization, the stem-loop structure undergoes a conformational change that 
allows it to adopt a linear format, thus causing a separation of the fluor and quencher from 
each other and the emission of maximum fluorescence. The use of hairpin primers is thought 
to increase the specificity of PCR assays by reducing primer dimer formation as well as 
mispriming. [99]. 
A study was carried out by Hazbon M.H and Alland D. (2004) [92] to determine the 
efficiency of these primers. This study was based on a similar principle to the Amplification 
Refractory Mutation (ARMS) method which distinguishes between the wild type and mutated 
nucleotide by making use of the relative inability of Taq polymerase to extend primers that are 
mismatched at their 3' ends. Primers are thus designed to be identical except for the 3 ' end 
nucleotide. The study compared hairpin primers with linear primers, and it was found that the 
assay which used hairpin primers was more sensitive for SNPs as the Ct values were greater. 
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2.7h Real-Time PCR 
2.7h (i) Goal of RT PCR 
Real-Time PCR has many applications in research since it combines the sensitivity of 
conventional PCR to the simultaneous detection of the PCR products while the amplification 
reaction is running [8 l]. This is achieved by incorporating a fluorescent DNA binding agent 
or probe into the PCR reaction, and the quantity of DNA can be assessed as the reaction 
proceeds by quantifying the amount of fluorescence. 
The speed at which the fluorescent signal reaches a threshold level depends on the amount of 
original target sequence, thus allowing quantification. If required, the PCR product or 
amplicon can then be further analyzed by determining its melting temperature through the 
generation of a me! ting curve [ I 00]. 
2.7h (ii) Advantages and Limitations of RT-PCR 
One of the important advantages of this method is its ability to quantify nucleic acids over a 
wide range. The method has also been found to be extremely sensitive, allowing the analysis 
of small quantities of DNA such as in clinical biopsies. This method is also very quick due to 
reduced cycle times and earlier product detection and also allows a high-throughput format. 
Since the PCR is performed in a 'closed' system that does not require any post-amplification 
manipulations, there is a great reduction in the possibility of the occurrence of any cross­
contamination [ 10 l]. 
As with any molecular technique, RT-PCR does have its limitations. One of these is the 
presence of PCR inhibitors in clinical samples that may not allow amplification to take place. 
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However, this problem may be overcome by choosing a DNA extraction technique, from the 
sample of interest, which allows for any possible PCR inhibitor to be removed. Another 
limitation is that only certain fluorescent chemistries can be used, depending on the machine 
used. This would be problematic in certain multiplex reactions. The biggest limitation is 
however, the cost involved in the design and manufacture of oligonucleotide probes and the 
price of the real-time instrument. 
2. 7h (iii) Amplicon Detection and Acquisition of Fluorescence
It is the detection of PCR products that distinguishes real-time PCR from conventional PCR. 
Real time chemistries consist of different specific and non-specific fluorescence reagents that 
bind to DNA, allowing monitoring of the PCR through the measurement of the fluorescent 
signal [81]. 
Non specific fluorescence reagents include the dyes ethidium bromide or SYBR green which 
bind to any dsDNA. However if specific fluorescence reagents such as labeled probes are 
used, the PCR signal corresponds specifically to the amplification of the target. 
2.7h (iv) Types of probes that can be used 
Different kinds of probes can be used. These include TaqMan or 5' nuclease probes, 
Molecular Beacons, hybridization probes and Scorpions which allow multiple DNA species to 
be measured in the same sample (multiplex PCR). Amplification products can be identified 
either by their different fluorescence spectra or by their melting characteristics or a 
combination of both [ I 02]. Probes can also be designed to discriminate between wild type and 
mutant sequences within the same DNA template [81]. Thus, although each probe has its own 
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unique characteristics, each works on the same basic concept [ 100]. The data generated by 
these probes are usually collected from PCR cycles that occur during the exponential phase of 
the amplification reaction. During this phase, conditions in all aspects are optimal for the 
assay [ 101]. 
1. Taqman probes
Conventionally, TaqMan probes used to be labeled with a fluorophore such as 6-carboxy­
fluoroscein (FAM) on the 5' end and a quencher fluorophore such as 6 carboxy tetramethyl
rhodamine (TAMRA) on the 3' end. However, an advancement of this technology includes 
the replacement of the TAMRA molecule with a minor groove binder (MGB), non-fluorescent 
quencher (NFQ) on the 3' end. The advantage that this replacement offers is threefold. Firstly, 
this results in the incorporation of a molecule that stabilizes the probe-target duplex [IO 1, 
103]. Secondly, due to the configuration of the probes, they are efficiently quenched. Thirdly, 
as a result of the interaction of the MGB with the DNA helix, short probes can be designed 
(thereby increasing the specificity of binding) due to them having a higher T111 • These probes 
are thus the probes of choice for detecting SNPs since they are easily destabilized by
nucleotide substitutions within the target site [ 10 l].
This donor acceptor dye pair of a TaqMan probe interacts via fluorescence resonance energy 
transfer (FRET). The probe anneals to the amplified target in each of the annealing steps of 
the PCR. While bound to its homologous sequence, the proximity of the fluor and quench 
molecules causes the quencher to absorb the signal from the reporter thereby preventing the 
detection of the fluorescent signal from the probe. During PCR, when the polymerase 
replicates a template on which a TaqMan probe is bound, the 5' nuclease activity of the 
polymerase cleaves the probe, causing a separation of the quencher from the dye. This allows 
the reporter's energy and fluorescent signal to be liberated. This fluorescence is measured by 
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the RT PCR instrument. However, fluorescence is only emitted if the probe is correctly 
anchored to its homologous site to allow the Taq polymerase to release the dye. This is the 
basis for the detection of mutations using TaqMan probes, if a mismatch occurs, this would 
prevent binding of the probe, resulting in no fluorescence being emitted. So depending on 
whether the probes are designed to hybridize to a wild type or mutant sequence, fluorescence 




Molecular Beacons form a stem loop structure when free in solution, with the loop consisting 
of the sequence which is homologous with the target DNA. In this configuration, the close 
proximity of the fluor and quench molecules prevents the probe from fluorescing. The stem­
loop structure is disrupted by the binding of the beacon to its homologous sequence in the 
target DNA thus separating the quencher from the dye which enhances the fluorescence. The 
principle is thus, in essence, very similar to the TaqMan probes. If a mutation occurs in the 
region covered by the probe, its binding to the target is impaired and the beacon remains in its 
stem loop conformation. Thus no fluorescence is emitted [ 104]. Molecular Beacons are able 
to discriminate between DNA sequences that differ from one another by as little as a single 
nucleotide substitution [46]. 
3. FRET Probes
Fluorescence resonance energy transfer probes are paired probes which are designed to anneal 
to the DNA template in a head-to-tail orientation with each probe close to the next. One probe 
referred to as the anchor is fluorescence labeled at its 3'end and the adjacent probe or sensor 
probe is labeled at the S'end with a dye which can be excited by the fluorescence of the 
anchor. The sensor probe is designed to overlap with the mutation which is to be searched for. 
When the FRET probes are correctly bound to their homologous target, by a process of energy 
transfer, excitation of the anchor dye stimulates the sensor dye, which in turn emits 
fluorescence. Mutation analysis, using this system, is performed in a melting step at the end of 
the PCR. The melting of the probe is represented as a melting peak with a melting temperature 
value. This T111 is constant for a pair of probes when bound to the wild type sequence. If a 
mutation occurs in the region covered by the probe, the mismatch between template and 
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probe, leads to a decrease in the Tm of the probes. The presence of a mutation is thus detected 
by a deviation in the melting temperature of the probe [ 104]. 
2.7h (v) Quantitation of Results 
Normalization 
The Passive Reference Dye is a dye that does not participate in the 5' nuclease assay. It 
provides an internal reference to which the reporter dye signal can be normalized during data 
analysis. For the ABI system, the dye used is a ROX dye which is a component of the 
Universal Master Mix used in the system. This process of normalization is required to correct 
for fluorescent fluctuations due to changes in DNA concentration or volume. Normalization is 
accomplished by dividing the emission intensity of the reporter dye by the emission intensity 
of the Passive Reference to obtain a ratio defined as the normalized reporter (Rn) for a given 
tube. Rn+ is the Rn value of a reaction containing all components including the template. Rn
is the Rn value of an unreacted sample. L'!.Rn is the difference between the Rn+ and the Rn­
value. It reliably indicates the magnitude of the signal generated by the given set of PCR 
conditions. The L'!.Rn is plotted against cycle numbers to produce amplification curves and 
give the Ct value. 
2.7h (vi) Applications of RT-PCR 
A rapid closed tube method was developed to detect common Mycobacterium tuberculosis 
mutations associated with resistance to isoniazid and rifampicin. The fluourogenic reporter 
molecules used in the study were molecular beacons. This method was found to be highly 
reliable as the overall sensitivity and specificity of the assay for isoniazid resistance was 85% 
and 100% respectively and for rifampicin resistance was 98% and 100% respectively [46]. 
37 
With regard to the rpoB gene, a single-tube PCR assay was developed to detect all mutations 
that occur in the Mycobacterium tuberculosis rpoB core region. Five different molecular 
beacons were used to assess resistance mutations that occurred at any point in the core region. 
The assay was found to be particularly useful as it was used on DNA extracted from sputum 
samples. The method also proved to be sensitive and rapid. It was also found to be very 
specific and easy to perform. Furthermore, from the results obtained, it was also possible to 
determine if a patient was infected with rifampicin-resistant TB and the concentration of 
bacilli present in the sample. All these findings pointed to a huge advancement in the 
treatment of TB, through an improvement of diagnostic and screening procedures for not only 
TB but MOR-TB as well [76]. 
A study was also carried out by de Viedma et al (2002) to develop a real time based PCR 
assay that would be able to detect rifampicin and isoniazid resistant bacteria in a single 
reaction tube. The method was advantageous in that it doesn't only search for the most 
prevalent resistance-conferring mutations in the rpoB core region but for most other 
resistance-conferring mutations as well. The assay also allows for the detection for the most 
prevalent resistnce conferring-mutations in the katG gene. However, the limitations of this 
study are firstly, that not all possible mutations that encode resistance for rifampicin are 
detected by the assay and secondly, some of the mutations detected may not be related to 
resistance, These limitations prompted the investigators of this study to encourage more work 
to be done on improving this method. Fu11her improvements have been achieved using probes 
capable of detecting eleven different mutations that confer resistance to both rifampicin and 
isoniazid within a period of just 2 hours. Fu11hermore, the Tms of each of the probes varied to 
such an extent that no overlap was found between susceptible and resistant strains [ 4 7]. 
38 
Prior to 2004, most of the RT-PCR assays were designed to detect mutations in DNA from 
cultured isolates [76, 104]. A study was therefore carried out to determine whether rifampicin 
and isoniazid resistance could be detected in DNA extracted from positive Auramine
Rhodamine staining (AR) sputum samples. The results of this study showed that in 
comparison to other molecular methods also used for this purpose, a lack of sensitivity was 
not observed. However, the one problem that was evident from this method is that for 
isoniazid resistance, the sensitivity of this method is only 53.8% [ 105]. A similiar study was 
then carried out by Marin M. et al (2004). This study was, however, a little more ambitious as 
it aimed at detecting multiple resistance mutations directly from clinical samples. In order to 
do this, two major changes were implemented in the research design. The first change 
required a change in the design of the RT-PCR assay so that the DNA strands complementary 
to the probes were preferentially amplified. The second change was that the three PCRs that 
amplified the 5' end of the rpoB gene, the 3' end of the rpoB gene and the katG gene were 
performed in three separate reaction tubes. This study was different from the study by Ruiz et 
al in two respects. Firstly, a wider variety of resistance-conferring mutations were assessed 
and secondly, sequence data was available, thereby allowing a comparison of RT PCR data 
with the 'gold standard' method of mutation detection. This method showed a 100% 
correlation with DNA sequencing and was also able to detect a much wider variety of 
mutations, including those that were not so common. (59]. 
Mixed populations of Mycobacterium tuberculosis occur frequently. This concept of a 
combination of both susceptible and resistant bacteria may therefore give a false perception of 
the phenotype of a particular culture [16]. Real-time PCR was therefore used to evaluate 
whether or not resistance-conferring SNPs could be identified in the presence of sensitive or 
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wild type alleles. The three different types of probes mentioned above were evaluated in the 
study. All probes were designed to target the wild-type or mutant allele at codon 531 of the 
rpoB gene or the wild-type or mutant allele at codon 315 of the katG gene. From the results 
obtained, it was found that molecular beacons and TaqMan probes can specifically detect 
individual alleles in a mixture but this depended on the ratio of the alleles and on the absolute 
quantity of each allele ( l :4.8 for low concentrations of allele and 1 :48 for high concentrations 
of allele). The detection levels reached by FRET probes could only compare to those reached 
by molecular beacons and TaqMan probes, after target enrichment by primary PCR thus 
making this technique a little less useful [43]. 
Another study was conducted by Hillemann 0. et al (2006) [ 106] to determine the sensitivity 
and specificity of RT PCR to detect Beijing and non-Beijing strains in a collection of MOR 
and fully susceptible isolates. Strains were analyzed using RT PCR, spoligotyping and the 
'gold standard' of TB 1S6110 fingerprinting. In this study, 103 MOR isolates were analyzed 
and the real-time assay correctly identified 62 isolates as Beijing genotypes and 41 isolates as 
non-Beijing genotypes. These results were based on the fact that Beijing genotype strains 
have a different distribution of resistance mutations as compared to non Beijing strains. There 
was also a 100% concordance between RT PCR and the results obtained using the other two 
methods. 
In another study carried out by Sajduda A. et al (2004) [ I 07] where clinical specimens were 
analyzed both by sequence analysis and RT-PCR technology, it was shown that the results 
found using both methods were comparable. Thus this group also reached the conclusion that 
RT-PCR is a fast and reliable method for the detection of isoniazid and rifampicin resistance­







3. Materials and Methods
3.1. Mycobacterium tuberculosis strains 
The assay was initially optimized using 15 Mycobacterium tuberculosis isolates obtained 
from Dr M Pillay and Mrs K.Ganas of the Department of Medical Microbiology at the 
University of Kwa Zulu Natal. These isolates were originally isolated as part of the Rapid 
Detection study and from the OFLOTUB Phase III clinical trial and were collected from 
Stanger, Umlazi, King George V hospital and from King Edward VIII hospital. All isolates 
had previously been tested for resistance to rifampicin and isoniazid and their susceptibility 
profiles for these two drugs are shown in table 4.1. In addition H37Rv (reference) was used as 
a reference strain. Spoligotypes and IS61 l O patterns were available for 7 of these isolates and 
they represented 3 genotypes including 2 KZN strains. 
3.2 Culturing of Mycobacterium tuberculosis 
Isolates which had been preserved in media containing Tryptic Soya Broth and glycerol at 
- 80
°
C, were thawed out and cultured in 5 ml of liquid 7H9 broth at 37
°
c until visible growth
occurred. Isolates were also subcultured onto Lowenstein-Jensen (LJ) media at 37
°
C from
existing cultures for a period of between 6-8 weeks. 
3.3 DNA Extraction 
3.3a DNA extraction from Lowenstein-Jensen media 
A loopfull of cells were transferred from the Lowenstein-Jensen (LJ) media into a 
microcentrifuge tube containing 500 µI l X TE (10 mM Tris-HCI [ph 8.0], l mM EDTA) 
buffer. The cultures were then heat-killed by incubation at 80°C for 30 minutes. 50 µI of 
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I0mg/mL lysozyme (Appendix 1) was then added to these heat killed bacteria. The mixture 
was then left to incubate for l hour at 37
°
C. 75 µI of a mix containing proteinase K 
( lOmg/mL) and 10% sodium dodecyl sulphate (SOS) (Appendix I) was then added to the 
lysosyme treated samples. After vortexing and 20 minute incubation at 65
°
C, 100 �d of 5M 
sodium chloride (NaCl) was added, followed by 100 µI of a mix of N, N, N trimethyl 
ammonium bromide (CTAB) and NaCl (Appendix 1 ). The mixture was then vortexed until it 
became 'milky' and then incubated for 20 minutes at 65
°
C. 750 µI of chloroform isoamyl 
alcohol was then added followed by vortexing and centrifugation at 12 000 g for 15 minutes. 
The aqueous supernatant was then transferred into fresh microcentrifuge tubes. 500 µI 
isopropanol was then used to precipitate the nucleic acids. These tubes were then left at -20
°
C 
for 30 minutes followed by a 30 minute centrifugation step. l mL of cold 70% ethanol was 
then used to wash the pellet followed by a 5 minute centrifugation. The supernatant was then 
discarded and the pellet left to dry at room temperature. The pellet was then dissolved in 20 µI 
of IX TE buffer [112, 113]. 
3.3b DNA extraction from 7H9 Broth 
Cultures were first transferred to 50 mL sterilin tubes and centrifuged at 12 000 g for 25 
minutes. The supernatant was discarded and the pellet re dissolved in 500 µI I X TE buffer. 
The cells were then heat killed by boiling at 95
°
C for 20 minutes. A DNA extraction was 
carried out using a similar method to the one described for the cultures from the LJ media, as 
described above, with the following exceptions: 
I. 70 µI instead of 50 µI of lysozyme was added to each sample.
2. 100 µl instead of 75 µl of a Proteinase K amd I 0% SOS mix was added to each sample.
3. 25 µI RNase was then added following the addition of the mix described above.
4. 200 µI of a mix of CTAB and NaCl was added instead of 100 µI.
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DNA precipitation was then carried out exactly as described above. 
3.3c DNA extraction from Ziehl Neelsen stained microscopic preparations 
The mineral oil was first removed from the slide with the addition of approximately 2 mL of 
xylene. Ziehl Neelsen-stained material was scraped off from the microscopic slides (using a 
clean, sterile blade for each slide) following the addition of 25 µl of triple distilled sterile 
water. The scraped material was then added to 25 µl of sterile distilled water in a 
microcentrifuge tube. 75 µl of Chelex suspension [ 114] was added. After a thorough 
vortexing of the samples, the samples were incubated at 97
°C for 30 minutes. The samples 
were then centrifuged at 13 000 g for l O minutes. The supernatant was then transferred to a 
1.5 mL microcentrifuge tube and used directly for PCR [30]. 
3.3d DNA extraction from sputum samples 
Three methods of extracting DNA from sputum samples were evaluated. 
i) DNA Extraction using Chelex
Sputum samples were first decontaminated and liquefied using the NALC/NAOH method 
(Appendix 2). The samples were then heat-killed for 15 minutes at 100°c. An equal volume 
of Inhibitor Removal Solution (IRS) { Appendix 4} was then added and the samples were 
incubated at 37°C for 10 minutes. Samples were then centrifuged at 12 000 g for 10 minutes 
and the supernatant discarded. The resulting pellet was washed with l mL sterile triple 
distilled water and centrifuged at 12 000 g for 10 minutes. The supernatant was then 
discarded. 75 µl of DNA Extraction solution (Appendix 4) was then added. The samples were 
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then incubated for 30 minutes at 95°C followed by a centrifugation step at 12 000 g for IO 
minutes. The supernatant was then used as a template in RT-PCR (modified from [ 115]). 
ii) DNA Extraction using the Silica Method
Samples processed by the NALC/NAOH method were first heat-killed by incubation for 15 
minutes at l00°C. I mL of lysis buffer (Appendix 5) was then added followed by the addition 
of 40 µI of acid washed silica (Appendix 5). The samples were then incubated for 15 minutes 
at room temperature with constant vortexing. This was followed by a centrifugation step at 12 
000 g for 30 seconds. The supernatant was then discarded. The resulting pellet was the 
washed twice with I mL wash buffer, vortexed and centrifuged for 30 seconds at 12 000 g. 
The supernatant was then discarded. The pellet was then washed twice, first with I mL and 
then with 500 µl of 70% ethanol and then centrifuged for 30 seconds at 12 000 g. Following 
the removal of the supernatant, the resulting pellet was washed once with I mL acetone and 
centrifuged for 30 seconds at 12 OOOg. The pellet was then air dried and 95 µI of I X TE 
buffer was added. The samples were then vortexed briefly followed by an incubation step at 
55°C for~ 10 minutes. The samples were then vortexed and centrifuged for 2 minutes at 12 
000 g. The supernatant was then transferred to a clean microcentrifuge tube and used as a 
template in RT-PCR (adapted from [ 116]). 
iii) Genotype® MTBDR DNA Extraction
Sputum samples were first decontaminated and liquefied using the NALC/NAOH method. 
500 µl of pretreated sputum samples were first centrifuged at 10 000 g for 15 minutes. The 
supernatant was then discarded and the pellet re-suspended in 100 µI sterile triple distilled 
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water. The samples were then heat inactivated at 100°c for 20 minutes. DNA was then 
extracted by ultrasonication using a Transsonic Digital S ultrasonic waterbath (60°C for 15 
minutes). Samples were then centrifuged at 10 000 g for 5 minutes. The supernatant was then 
used as a template for PCR [ 117]. 
3.4 Polymerase chain reaction amplification of drug resistance loci 
For the 15 isolates that was to be used in the development and the optimization of the RT­
PCR, amplification of both the katG and rpoB genes was carried out using oligonucleotides 
primers that have been previously designed for the amplification and sequencing of the codon 
315 region of the katG locus and the 'rifampicin resistance determining region' or RRDR 
region of the rpoB gene [87, 93] (table 3.1 ). Each reaction tube contained in a total volume of 
25 �tl, l X PCR buffer (Luci gen), 1.5 mM Magnesium chloride (MgCh), I 00 µM of each 
deoxyribonucleotide triphosphates (dNTP) (Fermentas], 1.25 U of EconoTaq DNA 
polymerase (Lucigen), 0.2 µM of each primer (Jnqaba) and 2.5 µI of Template DNA. 
Amplification was performed in the GeneAmp PCR System 9700 machine. Conditions for 
cycling were 94°C for 2 minutes, followed by 35 cycles of 94°C for l minute, 55°C for
minute and 72°C for 2 minutes, followed by an additional step at 72°C for 5 minutes. 
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Table 3. l: Primers used to amplify rpoB and katG genes for sequencing 
Target Oligonucleotides Product size 








3.5 DNA Sequencing 
The PCR products (katG gene or rpoB gene) were evaluated using agarose gel electrophoresis 
(Appendix 6). The amplified fragments (5 µI) were electrophoresed on a 2% agarose gel for 
1.5 hours at 100 V. Ethidium bromjde was used to stain the gel. The PCR products were then 
viewed under ultra violet (UV) light on the Vacutec Bio-imaging system. 12.5 ul of 
successful PCR reactions were sent to [nqaba biotech in Pretoria for sequencing 
(www.inqababiotec.co.za). Analysis of these gene sequences was then carried out by 
comparing them to the H37Rv genome (available at www.genolist.pasteur.frffuberculist). It 
was then determined whether the relevant mutation was present or absent in each gene. 
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3.6 Allele-Specific PCR 
3.6a) Primer Design 
Allele-Specific Primers were designed with the 3' end matching either the wild-type or 
mutant allele of the rpoB or katG gene and a reverse common primer. Primers were blasted 
against the H37Rv (reference) genome to ensure that the target sequences were in the correct 
region (www.genolist.pasteur.frffuberculist) Primers were also analyzed to check for 
hairpins, homo and heterodimers on www.idtdna.com. Primers were designed to have a Tm
between 58.3°C - 63.5°C and a length ranging from 14-27 base pairs. Common primers were 
designed with a T111 from 62
°C - 75°C with a length ranging from 22-30 base pairs. In the case
of the q;oB gene primers, a AG tail comprising a 12 bp nucleotide sequence was added to the 
wild type allele specific primer to favor allele discrimination. 
Table 3.2: Primers used in allele-specific PCR 
Name of primer Sequence 
rpoB rpoB.531.ttg.rev CGGGCCCCAGCGCCA All 
gene rpoB.531.wt.tail.rev GGAGGAGGAGGACGGGCCCCAGCGCCG primers 
rpoB.CP GGTGGTCGCCGCGATCAAGGAG designed 
katG.315.acc CGGTAAGGACGCGATCACCAC in this 
katG katG.315.wt CGGTAAGGACGCGATCACCAG study 
gene katG.CP.rev ACTCGTAGCCGTACAGGATC 
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3.6b) PCR conditions for allele specific PCR 
Initially each reaction tube contained in a total volume of 25 µl, nuclease free water, l X PCR 
buffer, l .5 mM MgCh, 100 µM of each dNTP, l.25 U of EconoTaq DNA polymerase, 0.2 
µM of each primer and 2.5 µl of Template DNA. Amplification was performed in the 
GeneAmp PCR System 9700 machine. Conditions for cycling were 95°C for 12 minutes,
followed by 40 cycles of 95
°c for 20 sec, 58
°
c for I minute and 72
°
c for 30 sec, followed by
an additional step at 72°C for 5 minutes [95]. Experiments were subsequently carried out to
optimize the annealing temperature, dNTPs concentration, MgC12 concentration, primer 
concentration and template concentration. These were as follows. 
i) Annealing Temperature - ln order to determine the optimal annealing temperature, the
initial annealing temperature used was estimated by calculating the Tm of the allele-specific 
primer. As a general rule, an annealing temperature 5
°
C lower than the Tm is often
satisfactory. However, the annealing temperature was varied whilst other conditions were kept 
constant in order to determine the optimal annealing temperature. 
ii) dNTPs and MgCh - Magnesium concentration is a crucial factor that can affect the success
of amplification. ln order for DNA polymerase to be active, adequate magnesium is required 
to form complexes with dNTPs, a substrate that the polymerase recognizes. The optimal 
MgC12 concentration varies between 0.5 mM and 5 mM and the final dNTP concentration 
should be between 50 µM and 500 µM. To determine the optimal MgC12 and dNTP 
concentration, experiments were carried out using varying concentrations of each component 
as shown in Table 3.3 while keeping all other reagent concentrations, in the PCR, constant. 
Thus each tube had a different concentration of dNTPs and MgC'2 while the concentrations of 
all other PCR reagents were kept constant. 
iii) Primers - Optimally 20 pmol of primers in a 50 µl reaction mix is the amount used. A
primer concentration higher than optimal may lead to mis-priming and accumulation of non-
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specific product while a concentration lower than optimal may lead to exhaustion of the 
primer before the reaction is completed. For optimization purposes, the PCR was carried out 
using the following concentrations of primers: 2 µM, 1 µM, 0.5 µM, 0.25 µM. The 
concentration of MgCh and dNTPs that produced optimal results was used with the above 
primer concentrations. The concentration producing the best result was chosen. 
iv) Template DNA - The amount of template required for successful amplification depends on
the complexity of the DNA sample. The DNA concentration was therefore varied to 
determine the optimal DNA concentration. The following concentrations of DNA were 
evaluated: 195.64 ng/µI, 14.64 ng/�tl, 2.48 ng/µl, 0.54 ng/µI and 0.20 ng/µl. 
v) Cycling conditions - After the above optimization experiments were carried out further
modifications to the conditions for cycling were made and the following conditions were 
used: 95°c for I 2 minutes, followed by 35 cycles of 95°c for 20 sec, 55°c for I minute and 
n
°
c for 30 sec, followed by an additional step at 72
°C for 5 minutes. 
Table 3.3: Optimization of MgCh and dNTPs 
50 µM dNTPs with: 100 µM dNTPs with: 150 µM dNTPs with: 200 µM dNTPs with: 
1.5 mM MgCl2 1.5 mM MgCl2 1.5 mM MgC!z 1.5 mM MgCh 
2.0 mM MgCl2 2.0 mM MgClz 2.0 mM MgClz 2.0 mM MgClz 
2.5 mM MgClz 2.5 mM MgCl2 2.5 mM MgCl2 2.5 mM MgCl2 
3.0 mM MgCh 3.0 mM MgCl2 3.0 mM MgCl2 3.0 mM MgCl2 
3.5 mM MgCl2 3.5 mM MgCl2 3.5 mM MgCl2 3.5 mM MgCl2 
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3.7 Real-Time PCR using allele-specific primers 
Reactions were performed in 96-well microtiter plates (MicroAmp 96-well optical reaction 
plate, Applied Biosystems). Each well contained a total volume of 25 µl of 1 X PCR buffer 
(Lucigen), 0.2 µM of each primer, 100 µM of each dNTP, 1 X SYBR green (Cambrex), 0.25 
µM ROX dye and 2.5 µl of template DNA. Amplification was performed in the ABI Prism 
7000 Sequence Detection System (ABI Prism 7000 SOS). Intitially the following conditions 
for cycling were used: 94
°
C for 3 minutes, 70
°
C for 30 sec, n
°
c for 30 sec, 94
°
c for 45 sec,
68
°
C for 30 sec, followed by 35 cycles of n
°
c for 30 sec, 94
°
C for 45 sec and 64
°
C for 30
sec, followed by an additional step at 72
°
C for 2 minutes. 
Cycling parameters were altered in subsequent experiments. There were 7 stages involved: 
Stage 1: 94
°
C for 3 minutes, 70
°C for 30 sec, n
°
c for 30 sec; Stage 2: 94
°
C for 45 sec , 69
°
C
for 30 sec, n°c for 30 sec; Stage 3: 94°C for 45 sec, 68
°
C for 30 sec, 72°C for 30 sec; Stage
4: 94
°
C for 45 sec, 67
°
C for 30 sec, n°c for 30 sec; Stage 5: 94
°
c for 45 sec, 66
°
C for 30 sec, 
72
°
c for 30 sec; Stage 6: 94
°C for 45 sec, 65
°
C for 30 sec, n
°





C for 30 sec, n°c for 30 sec (repeated for 35 cycles), followed by an additional 
72
°
c for 2 minutes. 
3.8 Real-time PCR using hairpin primers 
A different set of conditions were used to test a set of hairpin and linear primers. The primers 
tested for the Ser315Thr mutation are listed in table 3.4. All reactions were carried out in an 
ABI Prism 7000 SOS (Applied Biosystems) in a 96-well optical reaction plate. Reactions 
were carried out in 25 µI volumes containing nuclease free water, 1 X polymerase buffer, 1.25 
U of Taq polymerase, 0.2 µM of each primer, 100 µM of each dNTP and 1 X SYBR green 
(Cambrex). 2.5 µl of DNA was added to each tube to give a final reaction volume of 25 µl. 
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Two master mixes for each assay (hairpin and linear primer) were used, one that contained the 
mutant primer and the common reverse primer and another that contained the wild-type 
primer and the common reverse primer. The primers used in these experiments were designed 
using the Primer Express Software version 2 (Applied Biosystems). Primers were blasted 
against the H37R v (reference) genome to ensure that the target sequences were in the correct 
region (www.genolist.pasteur.frffuberculist). Thermal conditions were as follows for hairpin 
primers and linear primers: Stage l: 94
°
C for 3 min, 70°C for 30 sec, 12
°
c for 30 sec, Stage 2-
6, only the annealing temperature was changed by lowering by one degree for every 
subsequent cycle, Stage 7 ,  94°C for 45 sec, 64
°
C for 30 sec and n°c for 30 sec (repeated for
35 cycles) and Stage 8: 72°C for 2 min.
Table 3 .4: Primers used in the Hairpin Assay 
Name of Primer Sequence 
Hairpin HP _KatGS3 l5T_C AAACTGTTGTCCCATTTCGTCGG Primers 
primers HP _KatGS3 l5T_ WT CTGGTGATCGGTAAGGACGAGATCACCAG were 
HP _KatGS315T_MUT GTGGTGATCGGTAAGGACGAGATCACCAC designed 
Linear KatGS315T_ WT GGTAAGGACGAGATCACCAG m this 
primers KatGS315T_Mut GGTAAGGACGAGATCACCAC study 
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3.9 Real Time PCR using TaqMan probes 
3.9a) Design of TaqMan MOB probes and primers 
Two TaqMan MOB probes were designed for each gene to hybridize with either wild type 
DNA or mutant DNA. Primers for the rpoB gene were designed using the Primer Express 
Program, version 2 (Applied Biosystems). Primers for the katG gene were taken from 
published literature [118]. The MOB probes [118] were synthesized by Applied Biosystems 
while the primers were synthesized by Inqaba Biotech. A list of primers and probes are shown 
in table 3.5. Probes that hybridized with wild-type DNA were labeled with 6-
carboxyfluoroscein (FAM) (emission wavelength, 518 nm) at the 5' end and both with a 
MGB, NFQ at the 3' end. Probes that hybridized with the mutant sequence were labeled with 
VIC (emission wavelength, 552 nm) at the 5' end and with a MOB, NFQ at the 3' end. The 
advantage of using two dyes that emit luminescence of different wavelengths is that they can 
be individually distinguished in une tube thus allowing multiplexing by color to be carried 
out. 
3.9b) Amplification-hybridization assay 
Real-time PCR was performed in the ABI 7000 Sequence Detection System (Applied 
Biosystems) in a 96-well optical reaction plate format (Applied Biosystems). For a uniplex 
reaction, the PCR mixture was prepared in a final volume of 25 µl with 12.25 µl of Universal 
Master Mix (Applied Biosystems), 0.5 µM of each primer, 0.1 µM of the necessary probe and 
IO µl of purified DNA or extracted DNA. The initial conditions of PCR amplification were 
50°C for 2 minutes, 95°c for l O minutes and then 40 cycles of 95°c for 15 s and 60
°
C for l
minute. To increase discrimination between the two probes annealing temperature from 60°C 
to 65°C was changed for the first set of katG probes that were tested The PCR for the second 
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set of katG probes tested used the following conditions: 50°C for 2 minutes, 95
°C for lO 
minutes and then 40 cycles of 95°c for 15 s and 60°C for l minute. 
For the multiplex reaction, the pair of probes, wild-type and mutant, designed for each 
resistance codon were mixed m the same amplification reaction. The PCR mixture was 
prepared in a final volume of 25 µI with 12 µI of Universal Master Mix (Applied Biosystems), 
0.5 µM of each primer, 0.1 µM of each probe and lO µl of purified DNA or extracted DNA. 
The conditions of PCR amplification were 50°C for 2 minutes, 95°C for 10 minutes and then 
40 cycles of 95°C for 15 s and 65°C for t minute. 
Fluorescence of hybridized probes was expressed as �Rn (normalized reporter signal). The 
number of amplification signals required for emission of a certain luminescence intensity by 
each probe (�Rn = 0.2) reflected the amount of DNA in the sample. The cycle number is 
called the threshold cycle. Therefore the presence of a mutation would result in an increase in 
the Ct value. 
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Table 3.5: Primers and Probes used in RT- PCR 










GGGCTGGAAG AGCTCGT A TG 
#Taken from Wada T. et al., 2004 
*Taken from Espasa M.A. et al., 2005
Oligonucleotide probes 
*Wild-type probe:













5 '-FAM-TCACCAGCGGCA TC MGB-
NFQ-3' 
Mutant probe: 
5' VIC TCACCACCGGCA TC-MGB
NFQ-3' 
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3.10 Genotype® MTBDRplus 
Genotype® MTBDRplus is a commercially available multiplex PCR DNA strip assay (Hain 
Lifescience GmbH, Nehren, Germany) that is capable of simultaneously detecting mutations 
in the rpoB gene, the katG gene and in the regulatory region of the inhA gene. It thus allows 
for a rapid detection of not only the Mycobacterium tuberculosis complex but also its 
resistance to rifampicin and isoniazid in a single procedure. 
The principle of the test is based on the combination of a multiplex PCR and a reverse 
hybridization between the katG and rpoB biotin-labelled amplicons to membrane bound 
probes [ 117]. The DNA strip covers eight rpoB WT probes, four rpoB mutant probes, one 
katG WT probes, two katG mutant probes, two inhA WT probes and four inhA mutant probes. 
The strip is designed so that the most significant mutations in the rpoB gene (between codons 
507 533) are detected, for the testing of high-level isoniazid resistance, codon 315 of the 
katG is examined and for low level isoniazid resistance, the promoter region of the inhA gene 
is examined. 
The assay was carried out according to the manufacturer's instructions. In brief after DNA 
extraction (as outlined under the sputum DNA extraction methods above) amplification was 
carried out in a 50 µI reaction volume consisting of 35 µI primer-nucleotide mix (PNM) 
(provided with the kit), I X PCR reaction buffer (Roche Applied Science) containing 1.5 mM 
MgC12, 2 U of Taq polymerase (Roche Applied Science), 5 µl nuclease free water and 5 µl of 
extracted DNA using a GeneAmp PCR 9700 system (Applied Biosystems). The amplification 
profile consisted of a denaturation step (95°c for 5 min), 10 cycles of 95
°
C for 30 sec and 
58°C for 2 min, followed by 40 cycles of 95°c for 25 sec, 53
°C for 40 sec and 70
°
C for 40 sec 
followed by a final extension step of 70°C for 8 min. This was followed by reverse 
59 
hybridization. 20 µI of denaturation solution (provided with the kit) was added each of the 
wells followed by 20 µl of PCR product. After incubate for 5 min at room temperature, l mL 
of hybridization (HYB) buffer (pre-warmed to 45°C) was then added to each well, followed 
by a gentle shaking. A DNA strip was then added to each well and left to incubate in a 
shaking water bath/TwinCubator® for 30 min at 45°C. After complete aspiration of the HYB 
buffer, l mL of stringent wash solution (STR) (pre-warmed to 45
°C) was then added to each
well and left to incubate for 15 min at 45°C in the shaking water bath. The STR was then 
poured out and l mL of rinse solution (RIN) was added and left to incubate for l min at room 
temperature in the shaking water bath. Following removal of the RIN, l mL of diluted 
conjugate was added to each well and left to incubate for 30 min at room temperature in the 
shaking water. The solution was then removed and each strip was then washed twice for 1 
min with I mL RIN and once with I mL of distilled water on the shaking platform. l mL of 
diluted substrate (provided with the kit) was added to each strip and incubated at room 
temperature for 5 min without shaking. The reaction was stopped by briefly rinsing twice with 
distilled water. The strips were then removed from the tray using tweezers, dried on absorbent 
paper and pasted onto an evaluation sheet. Interpretation of the DNA strip was then carried 
out using the provided template according to manufacturer's instructions. All solutions were 




and 15 show negative controls. Lane 19 shows the molecular weight marker (Marker XIV 
( 100 bp ladder), Roche Diagnostics). 
Table 4.1 A comparison between susceptibility profiles and sequencing results for samples 
used in the optimization of the assay 
Isolate No Susceptiblilty profile Sequencin2 Results 
Isoniazid Rifampicin katG rpoB 
(lsoniazid) (Rifampicin) 
R376 R R Ser315Thr -
R377 R R no mutation Leu533Leu 
R380 R R Ser315Thr lle572Phe 
R383 s s - -
R387 R R Ser315Thr Ser531Leu 
R389 R R - Asp516Gly 
Leu533Pro 
KEH 65688 R s Ser315Thr -
KEH753ll R s Ser315Thr -
052450 (KLM) R R Ser315Thr Ser531Leu 
053338 (MTN) R R Ser315Thr Leu533Pro 
052951 (NOMI) R R Ser315Thr Ser531Leu 
052872(RIM) R R Ser315Thr Ser531Leu 
053051 (SHN) s R - Ser53 I Leu 
051298 (TBD) R R Ser315Thr Ser531Leu 
WP 68137 R R Ser315Thr -
denotes that strain was not sequenced 
As can be seen from the table, the sequencing results for samples that were sequenced 
correlated with the results as determined by susceptibility testing for all except one sample. 
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4.2 Allele-Specific PCR 
4.2. l Conventional PCR 
As an initial step to developing the ASP assay, primer pairs for the katG gene were tested 
under the same conditions as those outlined in the study carried out by Wang et al (2005) with 
the exception of the initial annealing temperature being at 60
°C, due to a slightly higher T111 of
the primers. The primer pairs used were katG.315.acc and katG.CP.rev for detection of the 
Ser315Thr mutation and katG.315.wt with katG.CP.rev for detecting the wild type sequence. 
PCR reactions were set up using genomic DNA from strains with or without the Ser3 l 5Thr 
mutation. No amplification was seen at this temperature so further experiments were carried 
out at annealing temperatures of 58°C and 55°C. Amplification was detected at the lower 
annealing temperature, but was inefficient as only faint bands were detected with gel 
electrophoresis. 
In order to improve the efficacy of the PCR, optimization of the dNTP and magnesium 
concentrations was carried out as explained in the methods section. Briefly, in each set of 
experiments, the dNTP concentrations and MgC12 concentration were altered and the efficacy 
of the PCR was determined using agarose gel electrophoresis. According to these experiments 
the optimal concentration of dNTPs was found to be I 00µM and the concentration of MgCb. 
1.5 m.M. 
Although improved amplification occurred using the altered parameters as described above, 
the PCR was not specific as both the WT as well as the mutant primers were amplifying all 
samples, irrespective of whether the samples had mutations or not. In order to increase the 
specificity of the primers the cycling parameters used were altered, and it was found that the 
mutant primer worked as it amplified only the samples with the Ser315Thr mutations. 
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However the wild-type primer still amplified with genomic DNA from H37Rv as well as 
DNA harboring the Ser315Thr mutation. 
A similar set of experiments was carried out using the rpoB primers that were designed as 
described in the material and methods section. In these experiments primer rpoB.531.ttg.rev 
was used in conjunction with primer rpoB.CP for the Ser531Leu and primer 
rpoB.531.wt.tail.rev with rpoB.CP for the wild type. Various annealing temperatures were 
tested between 65°C and ss0c, and the lower temperature of ss0c was found to be the
optimum (Figure 4.2) and gave adequate amplification when combined with the magnesium 
and dNTPs concentrations utilized for the katG gene. However the specificity of the rpoB 
primers for the mutation was excellent but the WT primers still amplified the samples with 
the mutation. 
This lack of specificity of both wild type primer sets could have been due to a number of 
factors. Contamination of the PCR reactions could be ruled out because negative controls 
consistently showed no amplification. An alternative explanation is that patients with drug 
resistant TB have been shown to harbor mixed populations of strains [ 119] which would 
result in templates for both primer sets coexisting in a single sample. To overcome this 
problem it was therefore decided to adopt a quantitative PCR methodology. 
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4.2.2 Quantitative PCR using SYBR Green 
The primer pairs' katG.315.acc and katG.CP.rev and katG.315.wt and katG.CP.rev were 
trialed in a quantitative PCR system using the ABI 7000 Sequence Detection System (Applied 
Biosystems) in conjunction with SYBR green. Conditions and reagent concentrations used 
were the same as those used in the conventional PCRs with the exception of the addition of a 
ROX reference dye and SYBR green. Although SYBR green is the most economical choice 
for RT-PCR product detection, it lacks specificity as its fluorescence is based on non-specific 
binding to any dsDNA 
However, the results from these experiments were similar to those with the conventional 
PCR. The WT primers showed amplification for both the wild type sample as well as the 
mutant sample while the mutant primers amplified only samples that contained the mutation 
These results were evident both from the amplification plot produced by the ABI 7000 SOS 




corresponds to the negative control. B) Amplification plot obtained using primers 
katG.315.acc and katG.CP.rev targeting the Ser315Thr mutation in the katG codon. The red 
graph was obtained using a template harboring the mutant sequence and green graph obtained 
with a wild type template. The x axis indicates the number of cycles of the PCR and the y axis 
is the Delta Rn. 
A comparison of figure 4.3 and figure 4.4 shows that for the same experiment, the negative 
control does not show any contamination when run on the gel but amplification is seen on the 
Delta Rn vs cycle curve from the ABI Prism 7000 SDS (blue curve). A possible explanation 
for this is that due to the lack of specificity of SYBR green, DNA other than the PCR product 
of interest was being detected at low levels by the ABI Prism 7000 SDS. However for the 
primers detecting the mutant sequence there was no difference between the negative control 
and amplification plot for the wild type template, but the plot for the mutant template was 
well separated with a threshold value 6 cycles earlier. In contrast the plots for the wild type 
primers indicated that there was no difference in amplification found with the wild type and 
mutant templates, again indicating poor specificity of this primer pair. 
Further optimization was therefore carried out, first by completely changing the cycling 
parameters. Further changes were made to the annealing conditions (for stages 2-6 the 
annealing temperature was dropped by one degree at each stage beginning at a temperature of 
69°C and ending at a temperature of 65°C), which still resulted in good specificity for the 
mutant probes which only amplified from the Ser3 l 5Thr samples but the WT primers 
amplified the DNA irrespective of whether the mutation was present or not. 
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Since there was no improvement in the specificity of the PCR, it was therefore decided to 





Further optimization was attempted by changing the concentration of the primers in the assay. 
All reagent concentrations remained the same, only the primer concentrations were altered 
over a range of 2µM to 0.25µM. The optimal primer concentration was found to be 0.5µM. 
However despite these promising results when the assay was tried on a larger number of 
samples the results were inconsistent and not reproducible. One possibility for this assay not 
working was the fact that the fluorogenic dye used, was SYBR green. Due to its lack of 
specificity, it binds to any dsDNA including primer dimers and other non-specific reaction 
products, thus any dsDNA present in the tube would have been detected. If specificity was 
difficult to achieve on genomic DNA extracted from culture it was unlikely that the assay 
would work directly on sputum. This prompted the change in methodology from ASP-PCR to 
a RT-PCR using TaqMan probes, which are innately more specific because fluorescence is 
contingent on the specific binding of a probe. 
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4.4 TaqMan Assay 
4.4. l Development of Assay 
Initial development of the assay was using TaqMan probes and primers from published 
literature [ 118). The assay was first attempted using H37R v DNA. The assay was first run 
separately, using two master mixes, one for the WT probe and one for the mutant probe. 
An experiment was carried out to determine the optimal DNA concentration for this assay. 
H37Rv was used exactly as it was extracted, then a 1:10 dilution was used and finally a 1:100 
dilution was used. The 'neat' DNA showed no amplification. A possible reason for this is that 
the DNA contained inhibitors. The ten fold dilution made no significant impact on the results 
of the RT-PCR assay. It was therefore decided to use a l: l 00 dilution for the assay. 
4.4.2 Optimization of TaqMan assay for Ser315Thr and Ser53 I Leu mutations 
These initial experiments used the same conditions as outlined in the study by Espasa et al
(2005) [ 118). However when the assay was carried out on genomic DNA from 15 isolates that 
were used in the development phase of the assay, a Ct value difference of just I was observed. 
To increase the discriminatory power of the probes, the annealing temperature was increased 
to 65°C since the probes were longer (22 bp) than the maximum length recommended by 
Applied Biosystems (20 bp). The concentration of the probe was also reduced from 0.2 �lM to 
0.1 µM. Results, using these conditions were shown to be a lot more favorable when 
compared to results produced by sequencing (Table 4.2). For the katG gene probes, all but l 
sample showed a correlation between the TaqMan results and sequencing results. One 
possible cause for this discrepancy between these two results is that of a mixed infection, in 
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which the sample contains two strains with different susceptibilities or one strain with both 
resistant and susceptible genotypes. 
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Table 4.2: A comparison of the results of DNA sequencing with a TaqMan assay using rpoB
probes for the Ser53 l Leu mutation and wild type rpoB sequence, and katG probes for 
Ser3 l 5Thr mutation and wild type katG sequence. 
Sample rpoB probe rpoB rpoB gene katG probe katG katG gene 
no Ct value TaqMan mutation Ct value TaqMan mutation 
Wt Mut Assay (sequencing) Wt Mut Assay (sequencing) 
Result Result 
R376 21.53 - Wt ND 23.76 19.35 Mut Ser315Thr 
R377 23.51 - Wt Leu533Leu 23.25 34.25 Wt no mutation 
R380 22.15 - Wt Ile572Phe 23.77 19.17 Mut Ser315Thr 
R383 22.43 - Wt ::.ND 22.37 30.67 Wt ::.ND 
R387 - 15.44 Mut Ser531Leu 24.34 20.29 Mut Ser315Thr 
R389 22.12 - Wt Asp516Gly 24.41 22.48 Mut KND 
Leu533Pro 
KEH 21.86 32.79 Wt ::.ND 28.85 23.54 Mut Ser315Thr 
65688 
KEH 21.66 27.80 Wt :sND 24.35 21. l l Mut Ser315Thr 
75311 
KLM - 19.47 Mut Ser531Leu 25.27 22.87 Mut Ser315Thr 
052450 
MTN 26.44 - Wt Leu533Pro 29.20 - Wt no mutation 
053338 
NOMI 20.83 - Wt Ser53 J Leu 24.96 22.52 Mut Ser315Thr 
052951 
Ser53 l Leu Ser315Thr 
RIM - 18.18 Mut 24.96 22.52 Mut 
052872 
SHN - 17.17 Mut Ser531 Leu 22.80 32.62 Wt :,ND 
053051 
TBD - 18.39 Mut Ser531Leu 27.47 24.95 Mut Ser315Thr 
05128
WP - 21.65 Mut Ser531Leu 27.32 32.72 Wt Ser315Thr 
68137 
RND corresponds to samples not sent for sequencing that were resistant on DST and 5ND to 
samples not sent for sequencing where DST found them to be susceptible. Mut corresponds to 
mutation detected by TaqMan assay and WT to wild-type detected by the assay. Samples 
whose TaqMan assay results did not correlate with sequencing results are shown in red. 
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Although the probes used for the rpoB assay were slightly shorter than the probes used in the 
katG assay, the GC content of the probes were quite similar. Therefore an annealing 
temperature of 65°C was also used in this assay. All other reagent concentrations and cycling 
conditions were also the same as those used in the katG assay 
For the 15 isolates mentioned previously, all except for I isolate showed a correlation 
between the TaqMan assay and sequencing results. The sample was shown to be susceptible 
by the TaqMan assay but resistant by sequencing. The same result was seen when the assay 
was repeated. 
At this point a multiplex PCR (using both probes in one master mix) was also carried out. 
Experiments were run in parallel using the same samples in a uniplex reaction and a multiplex 
reaction. Although the multiplex reactions worked, results from these experiments showed 
that the Ct values obtained in the multiplex reaction were a lot higher than those obtained in 
uniplex reactions and the difference in Ct values were a lot smaller too. It was therefore 
decided to run uniplex reactions instead of multiplex reactions. 
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4.4.3 Evaluation of TaqMan Assay on genomic DNA 
Genomic DNA was obtained from 24 more isolates whose susceptibility profiles were 
available. Of these samples, 10 were susceptible samples. For the katG gene, the remaining 14 
samples were sent to lnqaba biotech for sequencing. These samples were then used to further 
assess the TaqMan assay (Table 4.3). Once these samples were run on the TaqMan assay, all 
samples from which a result could be obtained correlated with sequencing results. 4 samples 
showed inconclusive results as no amplification occurred using either probe. A repeat of these 
samples showed the same results. A possible explanation for these results could be that there 
were PCR inhibitors present in the samples. 
For the same 24 isolates, for the rpoB gene, sequencing results for 21 isolates were available 
from a previous study. The remaining 3 isolates could not be sequenced as no DNA was 
available. Susceptibility results were however, available for all 24 isolates. According to the 
TaqMan assay 2 samples did not give expected results, and further 3 samples gave 
indeterminate results. 
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Table 4.3: Results from culture samples using the rpoB and katG TaqMan assay and 
sequencing results 
Sample rpoB probe rpoB rpoB gene katG probe katG gene 
no Ct values TaqMan results Ct values katG results 
Wt Mut assay (sequencing) Wt Mut TaqMan (sequencing) 
Result assay 
Result 
ROI 35.67 26.06 Mut Ser531Leu - 34.57 Mut Ser315Thr 
R02 44.20 16.01 Mut Ser531Leu - 20.72 Mut Ser315Thr 
Rl8 34.80 41.50 Wt KND - 38.19 Mut Ser315Thr 
R23 - 21.18 Mut no mutation - 31.69 Mut Ser315Thr 
R24 35.08 - Wt KND 44.43 - Wt no mutation 
R26 22.87 - Wt no mutation - 21.23 Mut Ser315Thr 
R32 - 21.93 Mut Ser531Leu - 27.98 Mut Ser3 l5Thr 
R43 30.84 - Wt no mutation - 31.99 Mut Ser3 l5Thr 
R47 28.40 49.55 Wt no mutation - 28.87 Mut Ser315Thr 
R54 - - no mutation * * no mutation 
R62 - - KND * * no mutation 
R79 24.01 24.48 Wt no mutation 31.36 33.23 Wt no mutation 
Rl03 30.48 33.61 Wt no mutation 46.12 46.12 Wt no mutation 
Rl04 39.79 39.85 Wt no mutation * * no mutation 
Rl25 37.32 46.46 Wt no mutation 58.17 - Wt no mutation 
Rl26 22.03 29.73 Wt no mutation 29.38 34.23 Wt no mutation 
Rl5 l 23.56 37.74 Wt no mutation 31.00 35.44 Wt no mutation 
Rl52 23.17 32.99 Wt no mutation 28.97 34.99 Wt no mutation 
R226 - 31.51 Mut Ser531Leu - 46.00 Mut Ser315Thr 
R300 29.53 18.26 Mut Ser531Leu - 25.61 Mut Ser315Thr 
R375 - - SND * * Ser315Thr 
R443 - 15.85 Mut S531L - 22.05 Mut Ser315Thr 
Ser531Leu 
R503 26.38 31.96 Wt SND - 26.86 Mut Ser315Thr 
R513 44.28 28.32 Mut SND 53.89 56.58 Wt no mutation 
* denotes samples who did not amplify despite 3 attempts with each sample.
5ND and RND denote samples which were not sent for sequencing or were no more DNA was
available. 5ND corresponds to susceptible b y  DST and RND corresponds to resistant. Wt
denotes that no mutation was detected b y  the assay; Mut denotes that the Ser315Thr mutation
was detected and no mutation denotes that sequencing results showed no mutation present in
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codon concerned (531 or 315). Samples whose TaqMan assay results did not correlate with 
sequencing results are shown in red. 
These promising results encouraged the attempt of a multiplex TaqMan assay. However, this 
assay did not produce satisfactory results as the Ct values obtained with both the WT and 
mutant probes were very similar. It was therefore decided to do each assay (one with the wild­
type probe and one with the mutant probe) separately. 
4.4.4 TaqMan assay using DNA extracted from slides 
The ability to detect resistance mutations in material extracted from a slide prepared for 
routine AFB microscopy would be an extremely useful surveillance tool. To determine if the 
TaqMan assay could be employed in this way, DNA was extracted from 20 slides by the 
method described by van der Zanden A.G.M. et al (2003) [30] and used as a template in the 
TaqMan assay. All the slides had been found to be smear positive. However, no amplification 
occurred in any of the samples. It was initially thought that there was not enough of DNA 
present in the sample, so a spiking experiment (with 14.64 ng/µl H37Rv DNA) was carried 
out on some of the DNA samples. Amplification did occur in two of the four samples when 
these spiked DNA samples were used as a DNA template in the TaqMan assay. This spiking 
experiment suggested that the failure of amplification was not only due to the presence of 
PCR inhibitors in the DNA and that the concentration of DNA extracted, was not high enough 
to be amplified by the ABI Prism 7000 SOS. 
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4.4.5 TaqMan assay on DNA from Sputum samples using different extraction methods 
The assay was then attempted using DNA from sputum samples. Eight decontaminated 
sputum samples were subjected to DNA extraction using both the silica method and the 
Chelex method. The samples were split into two 500 µl aliquots and the respective extraction 
methods performed. 
Prior to conducting a RT-PCR on these samples, their concentrations were first obtained using 
the Nandrop ND 1000 (table 4.4) 
The rpoB gene of all these samples were then amplified using conventional PCR and the 
products run on a gel. No products were detected from the samples extracted using the silica 
method, but four out of eight, although of differing band intensity, were detected from the 
samples extracted using the Chelex method. The DNA extracted using the Chelex method was 
then amplified by RT-PCR using the TaqMan assay and amplification did occur as a 
fluorescent signal was seen. Reagent and cycling conditions were the same as those used in 
the assay on culture isolates. 
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Table 4.4: Nanodrop results for DNA extracted from sputum samples using the Silica and 
Chelex methods. 
Chelex Silica 
Isolate no Concentration Concentration 
(ng/µ1) (ng/µl) 
5052 10.55 8.31 
5053 12.65 21.50 
5072 23.87 40.46 
5073 36.87 32.71 
5115 16.65 58.16 
5116 37.85 14.69 
5132 37.76 11.17 
5133 18.03 7.66 
The third method that was evaluated, the Genotype® MTBDRplus DNA Extraction also did 
not show any amplification with the TaqMan assay when tried on 6 different sputum samples 
This is a very crude DNA extraction method, which has been optimized specifically for the 
Genotype® MTBDRplus assay where no inhibitor removal was required. It was therefore 
decided to use the Chelex method to extract DNA from all clinical isolates used in the study. 
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4.4.6 Evaluation of TaqMan assay on DNA extracted from sputum samples using the 
Chelex DNA extraction method 
A collection of 140 sputum samples (which had already been decontaminated using the 
NALC/NAOH method) were obtained from Mrs Jenny Allen from the Department of 
Microbiology at the Nelson R Mandela School of Medicine. These samples were collected 
from TB suspects in the Department of Health (DOH) Drug resistance surveillance study 
carried out by the Medical Research Council (MRC). Susceptibility results and smear results 
for these samples were thus readily available. DNA was then extracted from these samples 
using the Chelex method. The DNA was then stored at -20°c until needed. 
Of the 140 samples, 120 of were then run using the optimized TaqMan assay for both the 
Ser315Thr mutation and the Ser53 I Leu mutation. 15 of these samples were AFB smear 
positive by auramine staining, and 32 of these samples were culture positive and DST results 
revealed 17 of the 32 were MOR and 2 were INH monoresistant. For each gene, 2 assays 
were run, one containing the WT probe and the other containing the mutant probe. The 
threshold value for these samples was set at 0.2 (Appendix 8) 
For the assays run on 87 samples that were culture negative 0/87 (0%), 1/87 (1.15%), and 
3/87 (3.44%) and 1/87 ( I. 15%) of the rpoB WT, rpoB Mut, katG WT and katG Mut and gave 
positive results respectively. These may correspond to false positive results although it is 
possible that they could represent true TB infection that failed to grow in culture. 
Amongst the 33 culture positive samples there were 12 samples that were smear positive, 18 
smear negative and three with unknown result because of the culture being contaminated. 9 of 
these gave a result with the rpoB probes of which 8 were smear positive and one of unknown 
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smear status. Of the 9 samples, 8 were MOR and l was isoniazid monoresistant. Results of 
the rpoB assay on the INH monoresistant strain were correct in that it was negative. Amongst 
the 8 MOR strains five were positive for the Ser5 3 l Leu mutation and three were wild-type, 
which gives an allele frequency of 62.5% amongst the MOR, similar to the results with the 
sequencing. 
For the katG assay, 9 out of the 33 culture positive samples gave results. Six samples of these 
9 were smear positive and l sample was smear negative. Furthermore, 2 samples gave results 
for both probes and both these samples were also smear positive. There were 5 MOR samples, 
I isoniazid monoresistant and I susceptible sample amongst the culture positive samples 
which gave results. The isoniazid monoresistant sample was also correctly identified by the 
assay. Amongst the 5 MOR samples, 2 or 40% had the Ser315Thr mutation which is slightly 
lower than the allele frequency as determined by sequencing. 
Table 4.5: Results of the RT-PCR assay and DST. 
DST Results 
RIF RIF INH INH Culture 
resistant sensitive resistant sensitive Negative 
rpoB 6/19 0/22 l/99 
TaqMan Ser531Leu (31.58%) (1.01 %) 
assay rpoBWT 3/19 5/22 0/99 
Results (15.79%) (22.73%) (0%) 
katG 3/21 0/20 l/99 
Ser315Thr (14.29%) (0%) (1.01 %) 
katG WT 5/21 7/20 4/99 
(23.81 %) (35.0%) (4.04%) 
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For each of the probes the number of positive tests over the total number of tests done is 
shown for the samples with the different susceptibility profiles. Percentages are the percent of 
postive results for each category of drug susceptibility. 
Table 4.6: Results of the RT PCR assay and DST (smear positive samples) 
DST Results 
RIF RIF INH INH Culture 
resistant sensitive resistant sensitive Negative 
rpoB 5/9 016 0/3 
TaqMan Ser53 l Leu (55.56%) (0%) 
assay rpoB WT 3/9 3/6 0/3 (0%) 
Results (33.33%) (50.0%) 
katG 3/11 0/4 (0%) 0/3 (0%) 
Ser315Thr (27.27%) 
katGWT 6/11 1/4 0/3 (0%) 
(54.54%) (25%) 
For each of the probes the number of positive tests over the total number of tests done is 
shown for the samples with the different susceptibility profiles. Percentages are the percent of 
postive results for each category of drug susceptibility. 
An additional 20 samples were also tested using a multiplex assay for evaluation. Of these, 12 
were culture negative, and 8 were culture positive but no amplification was seen with any of 
the samples (Appendix 8) 
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The results produced showed that the rpoB Ser53 l Leu assay was specific, with only 1 of 99 
culture negative samples testing positive. However only 31.58% of rifampicin resistant 
samples were accurately detected, indicating low sensitivity. This sensitivy did improve to 
55.56% on smear positive samples, an alleleic frequency compatible with the sequencing 
results in this study as well as previous studies. The rpoB WT probe faired less well as 
15.79% of drug resistant samples tested gave a positive result. Interestingly in the case of the 
katG probes the resistant probe also outperformed the sensitive probe. The probe to detect the 
Ser315Thr mutation was highly specific, but the wild type probe still gave positive results in 
35% of INH susceptible samples. It is unlikely that simple contamination could account for 
these discrepancies because there were very few positives results in the culture negative 
category, so it is more likely due to either mixed infection or binding of the probe to both 
resistant and susceptible sequences. In an attempt to improve the perormance of the katG
probe it was decided to redesign the probe as its length was 22 nucleotides which is 2 longer 
than the maximum recommended by Applied Biosystems. 
These probes were taken from a study by Wada T. et al (2004) and were shorter than the 
probes used previously in the study. The assay required no optimization as it was run under 
the same conditions as those outlined by the investigators of that study. 
The probes were first tested on 6 genomic DNA samples whose sequencing results were 
available. The probes identified 3 samples as being wild type and 3 samples as having the 
Ser315Thr mutation which corresponded with sequencing results. Further work will be 
required to determine if this probe could improve on the performance of the assay. 
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4.5 Genotype® MTBDRplus assay 
The aims of this thesis were to develop a high throughput tool for drug resistance 
surveillance. During the period of the optimization of the assay a commercially available 
Genotype® MTBDRplus assay became available for testing. This has been previously been 
shown to work well as a diagnostic test for MDR-TB (14], but has yet to be evaluated for use 
in surveillance. The results of this assay are interpreted by examining the banding patterns that 
form on each strip. These banding patterns are as a result of the hybridization of the single­
stranded, biotin-labelled amplicons, following a denaturation step, to membrane bound 
probes. Either the omission of a wild type band or the appearance of bands of DNA signals 
representing specific mutations indicates the existence of a resistant strain (65]. 
To evaluate the Genotype® MTBDRplus assay as a tool for surveillance 459 samples that 
were collected as part of a surveillance study for MDR-TB in KwaZulu-Natal were subjected 
to the Genotype® MTBDRplus assay. The results of these are presented below in table 4.7. 
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Table 4.7: Results for the Genotype® MTBDRplus assay 
Genotype® MTBDRplus result Number 
Rifampicin Result Isoniazid Result 
Resistant Resistant 18 
Resistant Susceptible 6 
Susceptible Susceptible 71 
Susceptible Resistant 5 
Indeterminate Susceptible 4 
Resistant fndetermjnate l 
Indeterminate Indeterminate 354 
Total 459 
88 of the 459 samples were found to be positive by auramine staining. Of these 88 smear 
positive samples, 23 gave an indeterminate result for both rifampicin and isoniazid resistance. 
Among the samples with a valid Genotype® MTBDRplus result 9 were found to be MOR, 48 
susceptible to both rifampicin and isoniazid, 4 RIF-monoresistant and 4 INH monoresistant. 
From the 459 samples Mycobacterium tuberculosis was isolated in 96 cases. The results of 
the Genotype® MTBDRplus assay by culture and smear results are displayed in table below. 
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Table 4.8: Results of the Genotype® MTBDRplus assay by culture and smear results 
Genotype® MTBDRp/us result 
Rifampicin Isoniazid Result Culture Smear Culture 
Positive Positive Negative 
Result 
Resistant Resistant 10 9 4 
Resistant Susceptible 4 4 0 
Susceptible Susceptible 49 48 10 
Susceptible Resistant 3 4 0 
Indeterminate Susceptible 1 0 0 
Resistant Indeterminate 0 0 0 
Indeterminate Indeterminate 29 23 122 
Total 96 88 136 
Full DST results were available for 36 samples all of which were found to be fully susceptible 
to both rifampicin and isoniazid. The Genotype® MTBDRplus assay results for these 36 
susceptible isolates was susceptible in 24 cases, indeterminate in 8 cases, MOR in I case and 
RIF-monoresistant in 3 cases. 
These results differ from previous published studies in that the indeterminate rate was high for 
both culture and smear positive cases, where the suspicion of TB is high. One possible 
explanation for this was the use of Roche Taq Polymerase, rather than the Qiagen Taq 
polymerase. Alternatively sample transit time from distant clinics might have led to DNA 
degradation. 
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The results of the Genotype® MTBDRplus assay (table 4.9) also confirm that the Ser315Thr 
mutation could be used for surveillance purposes since all isoniazid resistant isolates had this 
mutation. In the case of rifampicin resistance the Ser53 l Leu mutation was only found in 
38.89% of the MDR strains which is less than in most previous studies and suggests other 
mutations may need to be targeted for surveillance purposes. 
Table 4.9: Results for samples found to be positive for TB by the Genotype® MTBDRplus 
assay 
Mutation (as determined by Genotype® MTBDRplus 
assay) 
Ser531Leu Ser315Thr 
MDR-TB 7/18 (38.89%) 18/18 (100%) 
INH monoresistant 5/5(100%) 
RIF monoresistant 1/6 (16.67%) 




5.1 Allele Specific PCR 
Allele specific PCR has been demonstrated to be a technique capable of detecting point 
mutations in Mycobacterium tuberculosis when used on DNA extracted from cultured bacilli 
[71] [ 18, 19]. It is also a low cost method. However for the experiments run for the purposes
of this study, it has also been shown that considerable optimization is required to ensure that 
the assay works in the particular setting that one is working in. Assays run using the same 
reagent concentrations and cycling parameters as those outlined in these studies did not 
produce optimal results as expected. Furthermore all problems that were encountered 
occurred in assays that were run on genomic DNA only. It is important to note that more 
challenges will inevitably arise before the assay can be successfully run on crude DNA 
samples extracted from sputum. Thus, although the assay showed promise, the extensive 
optimization required for it to be applicable, suggested this type of assay might not be robust 
enough for use on clinical specimens. 
5.2 Hairpin Assay 
Hairpin assays have also been proven to be a successful way of improving the specificity of 
allele specific PCR [92]. Due to their unusual shape and the addition of a 'tail' to the 3' end of 
the primer, the primers need to be very carefully designed. Results presented in this study 
confirmed that these primers can be used successfully in allele-specific PCR and could be 
incorporated into an allele detection assay using differences in T111 • However given the 
difficulties in optimization that were encountered using this assay with SYBR green it was
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thought that it was not appropriate for the detection of mutations in sputum samples. One 
possibility would be to use a different fluorescent DNA binding reagent as has been 
successfully used by another group [ 120] but it remains to be seen if this type of mutation 
detection system can be successfully employed on sputum. 
5.3 TaqMan Assay 
As has been shown in previous studies both the rpoB and katG probes worked well on 
genomic DNA. The two mutations targeted in this study are very common in South Africa. In 
Kwa Zulu Natal, 97.5% of resistance-conferring mutations in the katG gene are Ser315Thr 
mutations [ 121], while for the rpoB gene, in a study carried out in Cape Town, the Ser53 l Leu 
mutation accounts for 76% of these mutations [14]. These mutations are therefore ideal for 
surveillance purposes. Ideally, a surveillance method should be high throughput method that 
can work on sputum specimens. 
5.3.1 DNA Extraction on Sputum samples 
The DNA extraction should be easy to perform, should not be too time consuming so as to 
allow a large number of samples to be completed in a day and deliver clean DNA on which a 
PCR can be performed. It should also be able to extract sufficient template from smear 
negative patients. For the purposes of carrying out both a conventional and RT PCR assay, 
many methods of DNA extraction for Mycobacterium tuberculosis have thus far been carried 
out. These include a TE boil extraction, an extraction using SDS and 10% Triton X, PrepMan 
extraction, Infection Diagnostics, Inc. (IDI) lysis extraction, Silica method and the Qiagen 
QIAmp DNA mini kit [ 122]. Problems encountered with these methods include the cost 
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effectiveness of the methods, the labor intensity as well as the time taken and the presence of 
inhibitory factors that may have been extracted along with the DNA. With regard to PCR 
inhibitors, a solution to this problem may be the use of magnetic particle-based technologies. 
Studies done thus far (123, 124]}[125] have indicated that magnetic bead DNA extraction is a 
reliable, simple, sensitive and safe method that removes any PCR amplification/enzyme 
inhibitors that might create problems for the following detection. 
For the purposes of this assay, as mentioned previously, three methods of DNA extraction 
were carried out. Of these, the Chelex method did give the best results but the method is still 
labor intensive and do not produce a very high yield of DNA. Work therefore needs to be 
done in a possible optimization of the Chelex method so as to reduce the time involved. Ways 
also needs to be found to improve the yield of DNA obtained. In this way, it is possible for 
the Chelex method to become a high throughput method. Another factor that could possibly 
be further looked into is the further optimization of the PCR. A more sensitive PCR would 
require a smaller volume of DNA. In this way it would possible to start off with a smaller 
volume of sputum deposit at the beginning of the extraction procedure. This would allow the 
extraction of DNA in a 96-well format using a multi-pipette. This would reduce the time, 
labor and reagents involved by processing a large number of samples at once. 
The Genotype® MTBDRplus assay was also found to be a very simple extraction procedure. 
However, it is a crude extraction method and was not found to work with the PCRs used in 
this study. It may be possible to co optimize the extraction and the TaqMan assay in such a 
way that both techniques can be used together and on a smaller volume of sputum. It should 
be noted that the Genotype® MTBDRplus assay does not yet perform well on smear negative 
samples. 
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5.3.2 katG PCR Optimization 
The sensitivity for any type of PCR is important. For the real-time assay, the probes initially 
used were from published literature yet still not produce satisfactory results. It is thus 
important to pay careful attention to the guidelines for probe and primer design as set out by 
the real-time machine that one is using. If design specifications such as melting temperatures, 
the GC content of the probe and the length of the probe are not strictly adhered to, then 
problems will arise. 
The other factor that may also be considered is that it may be necessary to work out the exact 
constituents of the master mix supplied by Applied Biosystems. This may enable one to 
design primers that are more sensitive, depending on the components of the master mix. This 
would allow a more sensitive PCR that uses a smaller volume of DNA and would also reduce 
the cost of the assay 
5.3.3 Sensitivity and Specificity 
Ideally a test should have a high sensitivity and specificity. However for a surveillance tool 
the sensitivity and specificity do not necessarily need to be as exacting as for a diagnostic 
tool. The aim is to be able to monitor drug resistance levels over time and across regions. If 
the assay performs consistently then valid trends and comparisons can be made. For further 
assay developed, a few areas need to be worked on or improved on, in order to increase the 
sensitivity and specificity of the assay. These include: I) Improving the DNA extraction 
method used, as mentioned previously, and searching for other DNA extraction methods that 
will improve the yield of DNA obtained; 2) The possibility of using a nested PCR in order to 
increase the target for the probe; 3) Further optimization of cycling conditions or a deviation 
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from default conditions; 4) The use of a custom made master mix using modified primers. 
This has been clearly done with success with the GenoType ® MTBDRplus assay since 
although a crnde DNA extraction method is employed, a successful PCR reaction can still be 
carried out; 5) For the samples used in this study, half of the sputum sample was cultured and 
the other half was used for the assay. Once the assay is proven to be working properly, and 
culture is not required for surveillance purposes, more sputum will be available for the assay. 
This will significantly improve the yield of DNA obtained and 6) it should be taken into 
consideration that smear positive samples gave better results than smear negative samples but 
the results were not high enough for the assay to be used for diagnostic purposes. It is not yet 
clear if MOR-TB is associated with smear status, but it may be possible to design a 
surveillance strategy based only on smear positive samples. 
Another factor that should be taken into consideration, which has been shown in the assays 
run, is that a sample can show 'negative results' in spite of the sample actually being positive. 
Of the 140 samples run using the TaqMan assay using both katG probe set l and the rpoB 
probe set, 28 samples although shown to be positive according to culture and susceptibility 
testing, did not give a result using any probe used in the assay. For samples that did not 
produce any results, it is possible that there were low quantities of DNA present initially so 
that undetectable levels of DNA remained. Another possible explanation for this is DNA 
degradation. If the samples are not stored at the correct temperature or left out at room 
temperature for too long periods of time such as in transit from the clinics then DNA 
degradation can occur prior to sample processing. 
This assay focused on mutations only in codon 315 of the katG gene and codon 531 of the 
rpoB gene. Besides being the most frequently encountered mutations, for the katG gene: l) 
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mutations m this codon were clearly associated with high isoniazid minimum inhibitory 
concentrations (MICs) [57, 71] and 2) the mutations in this codon were found to be markers 
of MDR-TB and strains with these mutations are easily transmitted [57). The results of the 
Genotype® MTBDRplus assay in this study also confirm that the Ser315Thr mutation is a 
good marker for surveillance in KwaZulu-Natal. For the rpoB gene, mutations in both codon 
531 and 526 are associated with high level resistance (MIC > 64 µg/rnL) [ 126, 127) [83) [ 42) 
[85). However the Genotype® MTBDRplus assay suggested that the Ser53 I Thr mutation was 
less common than in previous studies and surveillance would therefore need to target 
additional mutations in KwaZulu Natal. Another important factor to note is that this mutation 
is not only associated with resistance to rifampicin but all other rifamycins [85]. The above 
aspects were considered in the design of this assay in order to minimize the need to search for 
not-so relevant mutations but still search for the most relevant ones. 
Finally although the Genotype® MTBDRplus assay performed better that the RT PCR assay 
described in this thesis, there were still significant discrepancies when compared to DST 
results as well as indeterminate results in samples. In addition the need for a hybridization 
step and visualization of banding patterns may be a limitation to making the test genuinely 
high throughput. So although the RT PCR cannot yet replace the culture based phenotypic 
susceptibility test, it still has shown potential to become a rapid surveillance tool for MOR
and potentially XDR-TB. 
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Appendix 2: NALC/NaOH Sodium Citrate decontamination (TB lab SOP) 
Principle of Method 
N Acetyl-L-Cysteine (NALC) is a mucolytic agent that dissolves mucous material and
cellular material. This allows for the release of any mycobacteria present in the sputum 
sample. Sodium hydroxide (NaOH) decontaminates the sample while sodium citrate is added 
to stabilise the NALC by chelating any heavy metal ions that may be present in the specimen. 
Method 
• First wipe the outside of the sputum jar with disinfectant.
• Pour the specimen into a 50 mL centrifuge tube.
• Wipe the lip of the container.
• Add an equal volume of NALC working solution.
• Vortex the mixture for 15 minutes, until liquefied.
• If required, add extra NALC solution.
• Leave the mixture to stand for 15 minutes with regular vortexing, followed by the
addition of buffer to the 35 mL mark on the tube. (Buffer must be added to solution
within 20 minutes as mycobacteria are killed off if exposed to NaOH for too long a
period).
• Process negative and positive controls as samples.
• Centrifuge at 3000 g for 20 minutes.
• Decant the supernatant into concentrated phenol disinfectant.
• Resuspend the sediment by vortexing and inoculate 500 µl into a MGIT tube.
• Add 1 2 mL of 7H 11 buffer to the remaining deposit and vortex.
• 500 µl of this decontaminated sputum sample was then used for the DNA extraction
as described below.
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Appendix 3: Susceptibility testing of Mycobacterium tuberculosis: Modified proportion 
method (TB lab SOP) 
Principle of Method 
In this method, dilutions of inoculums are seeded onto both a control or drug free and a drug 
containing media so that countable colony forming units (CFU) of 50 100 are obtained on the 
control media. The numbers of CFU that grow on the drug containing medium is then 
compared on the control media. From this the population of bacilli resistant to a given drug 
can be calculated and expressed as a percentage of the total population tested. For the 
purposes of this study, only two drugs were looked at, isoniazid and rifampicin with drug 
susceptibilities of 1.0 and 1.0 respectively. 
Method 
Only positive cultures from 7H 11 agar plates and positive (mycobacterial growth indicator 
tube) MGIT tube (uncontaminated) are used in DST. 
3A) Setting up of susceptibilities from a No 1 MacFarland 
• 7H IO plates need to be brought to room temperature.
• Harvest several colonies with a sterile applicator stick.
• Inoculate into 4 mL tween buffer with beads and vortex for 1 2 minutes.
• Allow heavy particles of organisms to settle (15-20 minutes).
• Adjust supernatant to No l MacFarland Standard using sterile distilled water and
vortex to homogenize the solution.




• Use Pasteur pipettes to make the dilutions by adding 0.5 mL of the 10-
1 
dilution tube to
the next tube to make a I 0-
2 




• Inoculate the 1 % control quadrant with the 10-
4 
dilution with 0. I mL (3 drops with
Pateur pipette).
• Inoculate one plain plate (extra drug-free quadrant) with 10-3 dilution for extra growth
should it be required for repeating the susceptibility.
• Inoculate all drug quadrants with l 0-
2 
dilution tube by adding 0.1 ml to each drug
quadrant (3 drops).
• Tilt plates gently to spread the inoculums.
• Allow to air dry in the biosafety cabinet for ~2 hours or until dry.
• Pack into CO2 permeable plastic packets and seal.
• Incubate in the 37°C CO2 incubator for at least one week but not longer than two
weeks.
• Read susceptibilities after 21 days of inoculation.
3B) Setting up of susceptibilities if turbidity is less than a No 1 Macfarland 
• 7H IO plates need to be brought to room temperature.
• Only positive cultures from 7H 11 agar plates and positive (mycobacterial growth
indicator tube) MGIT tube (uncontaminated) are used in DST.
• Harvest several colonies with a sterile applicator stick.
• Inoculate into 4 mL tween buffer with beads and vortex for 1-2 minutes.
• Allow heavy particles of organisms to settle (I 5-20 minutes).
If, after pipetting the supernatant, the turbidity is less than a No 1 MacFarland, omit the 4th
dilution. The rest of the procedure is exactly as described above. 
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3C) Setting up of susceptibilities from a positive MGIT culture 
• If susceptibilities are to be done from positive MGIT cultures, the MGIT tubes must
have been inoculated for 1-2 days after becoming instrument positive.
• The MGIT tube acts as the 10- 1 dilution tube.
• Make 2 IO-fold serial dilutions ( 10-2 - 10-3).
• Use Pasteur pipettes to make the dilutions by adding 0.5 mL of the 10- 1 dilution tube to
the next tube to make a I 0-2 dilution. Continue in this fashion until a
10-4dilution is reached.
• Inoculate the I% control quadrant with the 10-3 dilution with 0.1 mL (3 drops with
Pasteur pipette).
• Inoculate one plain plate (extra drug free quadrant) with 10-2 dilution for extra growth
should it be required for repeating the susceptibility.
• Inoculate all drug quadrants with 10-2 dilution tube by adding 0.1 ml to each drug
quadrant (3 drops).
• Tilt plates gently to spread the inoculums.
• Allow to air dry in the biosafety cabinet for ~2 hours or until dry.
• Pack into CO2 permeable plastic packets and seal.
• Incubate in the 37°C CO2 incubator for at least one week but not longer than two
weeks.
• Read susceptibilities after 21 days of inoculation.
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Interpretation of results 
• Appropriate dilutions of inoculums are seeded onto both control and rug
containing media so that countable 50 100 CFU are obtained on at least one of the
control media.
• The numbers of CFU that grow on the drug containing medium is then compared
wit the number on the control media.
• A resistant strain will have growth on the drug containing media equal to or more
than 10% of colonies compared with the control media.
• A susceptible strain will have no growth on the drug containing media or less than
10% of colonies compared with the control media.
• An isoniazid intermediate strain will have no growth on the drug containing media
(isoniazid 1.0µ1/mL) but will have growth on the isoniazid 0.2µ1/mL drug
containing media when compared with the control media.
• Cultures of TB are usually obviously susceptible or obviously resistant and only
rarely are the results ambiguous.
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Appendix 4: DNA Extraction Using IRS and Chelex 
The Inhibitor Removal Solution (IRS) 
5M Guanidine Thiocyanate (OTC): 30 g 
50nM Tris HCl (pH 7.5): 5 mL of 500 nM Tris HCl 
25nM EDTA: 4.47 g 
0.5% Sarcosyl (N Laurylsarcosine): 0.25 g 
0.2M L-Mercaptoethanol: 0.78 mL 
Add OTC, EDTA, sarcosyl and mercaptoethanol to - 45 mL triple distilled water. Add 5 mL 
of 500 mM Tris-HCl, pH 7.5 to a final volume of 50 mL. 
NB: 1) IRS is stable for 2 months at room temperature if stored in an airtight container. 
2) IRS is prepared in a fume hood.
3) OTC containing waste is disposed of in !OM NaOH.
Extraction Solution 
Chelex: 1.2 g 
Tween 20: 36 µl 
Triton X 100: 3.6 µl 
Mix the Chelex, Tween and Triton X 100 in triple distilled water to a final volume of 10 mL. 
500 mM Tris-HCI 
Dissolve 3.028 g Trizma base in 30 mL triple distilled water and then adjust to a pH of 7.5 
and a final volume of 50 mL. 
0.2M EDTA (Ethylene Diamine Trichloro Acetic Acid) 
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Dissolve 37.22 g of EDTA in 500 mL and adjust pH to 7.5 using NaOH. 
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Appendix 5: DNA Extraction using the Silica Method 
Preparation of Acid Washed Silica: 2 day procedure (stable for 6 months at room 
temperature) 
• Add 6 g of SiO2 in 50 mL of triple distilled water, vortex thoroughly and allow to
settle at room temperature for 24 hours.
• Remove 43 mL of liquid, fill up to 50 mL, allow to settle for 5 hours at room
temperature.
• Remove 44 mL of fluid.
• Add 60 µl of lOM HCl to adjust the suspension to to pH 2.0.
• Store at room temperature in the dark.
Lysis Buffer 
• Dissolve 120 g of GTC in 100 mL of 0. lM Tris HCI, pH 6.4.
• Heat to 60°C to dissolve.
• Add 4.4 mL of 0.2M EDT A (pH 8.0).
• Add 500 µl TritonX 100.
Mix the solution by inverting. 
Wash Buffer 
• Dissolve 24 g GTC in 20 mL of 0. IM Tris-HCI, pH 6.4.
• Dissolve at 60°c.
Washing Ethanol 
Add 36.84 mL absolute ethanol to 0.125 mL 4M NaCl and fill up to 50 mL with triple 
distilled water. 
l l 6
Appendix 6: Gel Electrophoresis 
6A. lOX TBE (Tris-Borate-EDTA) Buffer 
• Measure out 108g Tris, 55g Boric Acid and 9.3g EDTA into a flask.
• Add 700 mL distilled water and dissolve at low heat.
• pH to pH 7.0 using HCI or NaOH as required
• Adjust volume to IL with distilled water.
• Filter and store at room temperature.
Sample Loading Buff er 
• Measure out 5 ml Tris-HCI, l ml EDTA (500 mM), 0.05g Bromophenol Blue and
300µ1 RN Ase ( 10 mg/mL).
• Add distilled water to a final volume of 100 mL
• Boil for 15 min at l 00°C and cool overnight.
6B. Procedure to make Agarose Gel 
For 2 % Gel (20 wells) 
• Measure out l .4 g of agarose into a flask, add 70 ml 0.5XTBE (Electrophoresis
buffer) and swirl.
• Place into a microwave oven, swirling occasionally until the agarose has dissolved.
• Cool to 40-50 °C and add 70 µI Ethidium Bromide
(Gloves must be worn when handling Ethidium bromide as it is mutagenic). 
• Set the gel casting tray and comb as required.
• Pour the warm agarose carefully ensuring that no bubbles form and allow
approximately 30 min to set at room temperature.
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Procedure to run the Gel 
• Remove combs from the gel
• Immerse gel into the buffer-filled (0.5X TBE buffer) tank.
• Add more 0.5X TBE buffer into the gel tank to ensure that the gel is completely
covered.
• Pipette 3 µl of gel loading buffer per sample onto a piece pf parafilm.
• Add 5 µl of sample to the loading gel, mix well and add into the gel wells.
• Place the lid of the gel tank into position and ensure the electrodes are correctly
connected, switch on the power supply.
• Since DNA is negatively charged, the gel runs towards the positive electrode.
• Leave the gel to run at 100 Volts for approximately 60 to 90 min.
• Remove gel from tank.





Appendix 8: Table showing results of sputum samples analyzed using TaqMan assay 
Table 8A : Table showing results of sputum samples analyzed using TaqMan assay: rpoB and 
first set of katG probes, smear results and susceptibility results 
Laboratory Patient MOS Smear Susceptibilty rpoB katG 
No Initial No result result 
RIF INH Wt Mut Wt Mut 
5245 SBM MOS 3+ R R - 38.30 37.93 -
1009 
5238 BLG MOS NEG R R - - - -
1014 
5451 NL MOS 3+ R R - - - -
1029 
5277 NN MOS NEG - - - - - -
1035 
5265 HG MOS NEG - - - - - -
1036 
5267 PN MOS NEG s s - - - -
1037 
5259 MN MOS - - - - - - -
1038 
5262 MP MOS NEG - - - - - -
1039 
5260 MF MOS NEG - - - - - -
1040 
5261 BM MOS NEG - - - - - -
1041 
5269 MS MOS NEG - - - - - -
1043 
5273 TN MOS 2+ - - - - - -
1046 
5258 SG MOS l+ - - - - - -
1047 
5266 IM MOS NEG - - - - - -
1049 
5257 AM MOS NEG - - - - - -
1050 
5274 PM MOS 2+ - - - - - -
1051 
5264 HM MOS NEG s s - - - -
1053 
5272 DN MOS 2+ s s - - - -
1054 
5291 MG MOS NEG - - - - - -
1055 
5287 NM MOS NEG - - - - - -
1056 
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Laboratory Patient MOS Smear Susceptibility rpoB katG 
No Intitials No results results 
RIF INH Wt Mut Wt Mut 
5284 TM MOS NEG - - - - - -
1057 
5290 BM MOS NEG - - - - - -
1058 
5282 MM MOS NEG - - - - - -
1059 
5289 FG MOS NEG - - - - - -
1060 
5280 LM MOS NEG - - - - - -
1061 
5281 NM MOS NEG s s - - - -
l062 
5288 BM MOS NEG - - - - - -
1064 
5285 NM MOS NEG - - - - - -
1065 
5283 MJ MOS NEG s s - - - -
1066 
5342 MM MOS NEG - - - - - -
1067 
5335 TN MOS NEG - - - - - -
l068 
5337 DO MOS NEG - - - - - -
1069 
5345 MT MOS NEG - - - - - -
1070 
5339 JM MOS NEG - - - - - -
1071 
5338 ME MOS NEG - - - - - -
1072 
5346 SM MOS NEG - - - - - -
1073 
5333 ss MOS NEG - - - - - -
1074 
5341 MT MOS NEG - - - - - -
1075 
5340 MN MOS NEG - - - - - -
1076 
5336 MM MOS NEG - - - - - -
1077 
5334 GP MOS NEG - - - - - -
1079 
5344 TZ MOS l+ s s - - - -
1080 
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Laboratory Patient MOS Smear Susceptibility rpoB katG 
No Initials No results results 
R[F INH Wt Mut Wt Mut 
5343 MJ MOS NEG s s - - - -
1081 
5371 MB MOS NEG - - - - - -
1082 
5380 MN MOS NEG - - - - - -
1083 
5375 MT MOS NEG - - - - - -
1084 
5365 LM MOS NEG - - - - - -
1085 
5373 SN MOS NEG - - - - - -
1086 
5370 ss MOS NEG - - - - - -
1087 
5367 NM MOS NEG - - - - - -
1088 
5364 BN MOS NEG - - - - - -
1089 
5374 SM MOS NEG - - - - - -
1090 
5368 SN MOS NEG - - - - - -
1091 
5379 LN MOS NEG - - - - - -
1092 
5381 MM MOS NEG - - - - - -
1093 
5361 VD MOS NEG - - - - - -
1094 
5372 MT MOS NEG - - - - - -
1095 
5378 MM MOS NEG - - - - - -
1096 
5362 ST MOS NEG - - - - - -
1097 
5366 NZ MOS NEG - - - - - -
1098 
5369 vs MOS NEG s s - - 38.15 -
1099 
5377 MT MOS NEG - - - - - -
1100 
5363 NL MOS NEG - - - - - -
110 I 
5459 BG MOS NEG - - - - - -
1104 
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Laboratory Patient MOS Smear 
No Initials No results Susceptibility rpoB katG 
results 
RIF INH Wt Mut Wt Mut 
5466 TN MOS NEG - - - - - -
1105 
5474 SN MOS NEG - - - - - -
1106 
5473 MN MOS NEG - - - - - -
1107 
5462 KM MOS NEG - - - - - -
1108 
5461 MR MOS NEG - - - - - -
1109 
5470 MS MOS NEG - - - - - -
1111 
5475 KM MOS NEG - - - - - -
1112 
5472 SM MOS NEG - - - - - -
1114 
5460 MT MOS NEG - - - - - -
11 I 6 
5465 NM MOS SC s s - - - -
1117 
5469 KB MOS SC - - - - - -
1119 
5468 AH MOS NEG - - - - - -
1120 
5467 TZ MOS NEG - - - - - -
1121 
5484 MS MOS NEG - - - - - -
1122 
5483 MJ MOS NEG - - - - - -
1123 
5488 MM MOS NEG s s - - - -
1124 
5489 DD MOS NEG s s - - - -
1129 
5527 NB MOS NEG - - - - 41.35 -
1130 
5518 NI MOS NEG - - - - 40.48 -
1134 
5587 ZD MOS NEG R R - - - -
1151 
5622 RM MOS NEG - - - - - -
l I 61
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Laboratory Patient MOS Smear 
No Initials No results Susceptibility rpoB katG 
results 
RIF INH Wt Mut Wt Mut 
5623 LT MOS NEG s s - - - -
1162 
5616 TM MOS NEG - - - - - 44.09
1163 
5620 GM MOS NEG s s - - - -
1164 
5619 SN MOS NEG - - - - - -
1165 
5617 MM MOS NEG - - - - - -
1166 
5618 SM MOS NEG - - - - - -
1167 
5704 LN MOS NEG - - - 42.95 -
1168 
5701 BM MOS NEG - - - - - -
1169 
5699 PM MOS NEG - - - - - -
1170 
5703 MO MOS NEG - - - - - -
1171 
5705 BG MOS NEG - - - - - -
1173 
5700 SN MOS NEG - - - - - -
1174 
5707 ZN MOS NEG - - - - - -
1175 
5698 SM MOS NEG - - - - - -
1176 
5699 TS MOS NEG - - - - - -
1177 
5706 ZN MOS NEG - - - - - -
1179 
5702 TT MOS 2+ s R 41.23 - 39.82 -
1180 
5702 TT MOS 2+ s R - - - -
1180 
5719 ML MOS NEG - - - - - -
118 l 
5718 MS MOS NEG - - - 42.99 - -
1182 
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Laboratory Patient MOS Smear Susceptibility rpoB katG 
No Initials No results results 
RIF INH Wt Mut Wt Mut 
5717 BP MOS NEG - - - - - -
1183 
5797 NB MOS NEG R R - - - -
1196 
5857 PM MOS 2+ R R - 33.39 40.07 -
1229 
5849 SN MOS NEG R R - - - -
1232 
5850 MN MOS 3+ R R - 34.82 44.18 -
1233 
5879 DN MOS NEG R R - - - -
1242 
5876 BN MOS 3+ R R 29.51 - - -
1246 
5883 SD MOS NEG R R - - - -
1248 
6010 SM MOS ? R R - - - -
1281 
6015 TF MOS NEG R R - - - -
1283 
6076 TD MOS 2+ R R 38.24 - 41.60 43.79 
1301 
6093 KN MOS ? R R - 33.52 - -
1307 
0289 MS MOS ? s s - - - -
1354 
0860 NM MOS I+ R R 43.64 - 42.56 42.73 
1376 
1999 MN MOS l+ R R - 35.84 - -
1470 
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Table 8B: Table showing results of sputum samples analyzed using TaqMan assay: rpoB and 
first set of katG probes (multiplex PCR), smear results and susceptibility results 
Laboratory Patient MOS Smear Susceptibility rpoB katG 
No Initials No results results 
RIF INH Wt Mut Wt Mut 
5241 MM MOS 3+ s s 33.16 - - -
1001 
5244 PG MOS NEG s s - - - -
1002 
5243 JB MOS NEG s s - - - -
1003 
5236 GM MOS 3+ s s 36.50 - 38.62 -
1004 
5237 CD MOS NEG - - - - - -
1005 
5240 MS MOS NEG s s - - - -
1007 
5235 DS MOS NEG - - - - - -
1008 
5245 SBM MOS 3+ R R - 30.38 - 33.08 
1009 
5246 DM MOS NEG - - - - - -
1010 
5247 SM MOS NEG - - - - - -
1011 
5248 EM MOS NEG - - - - - -
1012 
5239 MZ MOS NEG s s - - - -
1013 
5238 BLG MOS NEG R R - - - -
1014 
5242 ZT MOS NEG - - - - - -
1015 
5234 TO MOS NEG - - - - - -
1016 
5252 SM MOS NEG - - - - - -
1031 
5253 PN NEG - - - - - -
5256 MB MOS NEG - - - - - -
1044 
5254 SN MOS NEG - - - - - -
1048 
5255 AP MOS NEG - - - - - -
1052 
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Appendix 9: Figure showing rpoB gene, with position of relevant primers and probes 
M. tuberculosis H37Rv!Rv0667lrpoB: 3519 bp - DNA-DIRECTED RNA POLYMERASE
(BETA CHAIN) RPOB (TRANSCRIPTASE BETA CHAIN) (RNA POLYMERASE BETA SUBUNIT)
1 - ttg gca gat tee cgc cag age aaa aca gee
31 - get agt cct agt ccg agt cgc ccg caa agt 
61 - tee tcg aat aac tee gta CCC gga gcg cca 
91 - aac egg gtc tee ttc get aag ctg cgc gaa 
121 - cca ctt gag gtt ccg gga etc ctt gac gtc 
151 - cag ace gat tcg ttc gag tgg ctg ate ggt 
181 - tcg ccg cgc tgg cgc gaa tee gee gee gag 
211 - egg ggt gat gtc aac cca gtg ggt ggc ctg 
241 - gaa gag gtg etc tac gag ctg tct ccg ate 
271 - gag gac ttc tee ggg tcg atg tcg ttg tcg 
301 - ttc tct gac cct cgt ttc gac gat gtc aag 
331 - gca CCC gtc gac gag tgc aaa gac aag gac 
361 - atg acg tac gcg get cca ctg ttc gtc ace 
391 - gee gag ttc ate aac aac aac ace ggt gag 
421 - ate aag agt cag acg gtg ttc atg ggt gac 
451 - ttc ccg atg atg ace gag aag ggc acg ttc 
481 - ate ate aac ggg ace gag cgt gtg gtg gtc 
511 - age cag ctg gtg egg tcg CCC ggg gtg tac 
541 - ttc gac gag ace att gac aag tee ace gac 
571 - aag acg ctg cac age gtc aag gtg ate ccg 
601 - age cgc ggc gcg tgg etc gag ttt gac gtc 
631 - gac aag cgc gac ace gtc ggc gtg cgc ate 
661 gac cgc aaa cgc egg caa ccg gtc ace gtg 
691 - ctg etc aag gcg ctg ggc tgg ace age gag 
721 - cag att gtc gag egg ttc ggg ttc tee gag 
751 - ate atg cga tcg acg ctg gag aag gac aac 
781 - ace gtc ggc ace gac gag gcg ctg ttg gac 
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1741 - gtg tcg gtg gee ace gcg atg att CCC ttc
1771 - ctg gag cac gac gac gee aac cgt gee etc
1801 - atg ggg gca aac atg cag cgc cag gcg gtg
1831 - ccg ctg gtc cgt age gag gee ccg ctg gtg
1861 - ggc ace ggg atg gag ctg cgc gcg gcg ate
1891 - gac gee ggc gac gtc gtc gtc gee gaa gaa
1921 - age ggc gtc ate gag gag gtg tcg gee gac
1951 - tac ate act gtg atg cac gac aac ggc ace
1981 - egg cgt ace tac egg atg cgc aag ttt gee
2011 - egg tee aac cac ggc act tgc gee aac cag
2041 - tgc CCC ate gtg gac gcg ggc gac cga gtc
2071 - gag gee ggt cag gtg ate gee gac ggt CCC 
2101 - tgt act gac gac ggc gag atg gcg ctg ggc
2131 - aag aac ctg ctg gtg gee ate atg ccg tgg
2161 - gag ggc cac aac tac gag gac gcg ate ate
2191 - ctg tee aac cgc ctg gtc gaa gag gac gtg
2221 - etc ace tcg ate cac ate gag gag cat gag
2251 - ate gat get cgc gac ace aag ctg ggt gcg
2281 - gag gag ate ace cgc gac ate ccg aac ate
2311 - tee gac gag gtg etc gee gac ctg gat gag
2341 - egg ggc ate gtg cgc ate ggt gee gag gtt
2371 - cgc gac ggg gac ate ctg gtc ggc aag gtc
2401 - ace ccg aag ggt gag ace gag ctg acg ccg
2431 - gag gag egg ctg ctg cgt gee ate ttc ggt
2461 - gag aag gee cgc gag gtg cgc gac act tcg
2491 - ctg aag gtg ccg cac ggc gaa tee ggc aag
2521 - gtg ate ggc att egg gtg ttt tee cgc gag
2551 - gac gag gac gag ttg ccg gee ggt gtc aac
2581 - gag ctg gtg cgt gtg tat gtg get cag aaa
2611 - cgc aag ate tee gac ggt gac aag ctg gee
2641 - ggc egg cac ggc aac aag ggc gtg ate ggc
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Appendix 10: Figure of the katG gene, with position of relevant primers and probes 
M. tuberculosis
PEROXYNITRITASE
1 - gtg CCC 
31 - ace ace
61 - CCC gtc 
91 gag ggc
121 - aac egg
151 - aac ccg
181 - gcg ttc
211 - ate gac
241 - gag gaa
271 - tgg CCC 
301 - ctg ttt 
331 - ggc ace 
361 - ggc gee 
391 - ccg ctt
421 - ttg gac
451 - gtc aag
481 - tgg gcg
511 - tgc gcg
541 - ttc ggg
571 - tgg gag 
601 - gaa gee 
631 - age ggt
661 - gee gcg
691 - aac ccg
721 - CCC atg
751 - acg ttt 































gee get age 
cat atg aaa 
aac cag gac 
ctg aag gta 
get gac ccg 
gee gcg gag 
gee ctg acg 
ace ace tcg 
tac ggc cac 
atg gcg tgg 
ate cac gac 
ggc atg cag 
tgg CCC gac 
cgc egg ctg 
tac ggc aag 
att gtt ttc 
tcg atg ggc 
ttc ggc egg 
gag gtc tat 
etc ggc gat 
gat ctg gag 
atg ggg ctg 
ccg aac ggc 
gcg gtc gac 
atg gee atg 
ctg ate gtc 
2223 bp - CATALASE-PEROXIDASE-
att aca gaa 
aac ggc tgt 
tac CCC gtc 
tgg tgg CCC 
ctg cac caa 
atg ggt gcg 
gtc gcg ace 
egg gac ate 
cag ccg tgg 
tac ggg ccg 
cac get gee 
ggc cgc ggc 
egg ttc gcg 
aac gee age 
ctg tgg ccg 
aag etc tea 
gee ggc aac 
ttc aag acg 
gtc gac cag 
tgg ggc aag 
gag cgt tac 
aac ccg ctg 
ate tac gtg 
aac ccg gac 
att cgc gag 
aac gac gtc 
ggc ggt cac 
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1741 - gtg gaa tee ttt gee gtg ctg gag CCC aag
1771 gca gat ggc ttc cga aac tac etc gga aag
1801 - ggc aac ccg ttg ccg gee gag tac atg ctg
1831 - etc gac aag gcg aac ctg ctt acg etc agt
1861 - gee cct gag atg acg gtg ctg gta ggt ggc
1891 - ctg cgc gtc etc ggc gca aac tac aag cgc
1921 - tta ccg ctg ggc gtg ttc ace gag gee tee
1951 gag tea ctg ace aac gac ttc ttc gtg aac
1981 - ctg etc gac atg ggt ate ace tgg gag CCC 
2011 - tcg cca gca gat gac ggg ace tac cag ggc
2041 - aag gat ggc agt ggc aag gtg aag tgg ace
2071 - ggc age cgc gtg gac ctg gtc ttc ggg tee
2101 - aac tcg gag ttg egg gcg ctt gtc gag gtc
2131 - tat ggc gee gat gac gcg cag ccg aag ttc
2161 - gtg cag gac ttc gtc get gee tgg gac aag
2191 - gtg atg aac etc gac agg ttc gac gtg cgc
2221 - tga
135 
Appendix 11: Showing sequencing results 






























































































































































































































































































































































































































































Appendix 11 B: rpoB samples sent for DNA sequencing 
R377 
CGTACTCCACCGTCGCCCGCCCTTGCGGCGGACAGCACGCGCGGCTCGACGAAGCGACCG 
TCCGCATCGATCGGCGAATTGGCCTGTGCCACCACGTGGCGGTCCTCCTCGTCGGCGGTC 
AGGTACACGATCTCGTCGCTAACCACGCCGTCGACCACCTTGCGGTACGGCGTTTCGATG 
AACCCGAACGGGTTGACCCGCGCGTACACCGACAGCGAGCCGATCAGACCGATGTTGGGC 
CCCTCAGGGGTTTCGATCGGGCACATCCGGCCGTAGTGCGACGGGTGCACGTCGCGGACC 
TCCAGCCCGGCACGCTCACGTGACAGACCGCCGGGCCCCGGCGCCGACAGTCGGCGCTTG 
TGGGTCAACCCCGACAGCGGGTTGTTCTGGTCCATGAATTGGCTCAGCTGGCTGGTGCCG 
AAGAACTCCTTGATCGCGGCGACCACCGGCCGGATGTTGATCAACGTCTGCGGTGTGATC 
GCCTCCACGTCCTGGGTGGTCATCCGCTCCCGGACCACCCGCTCCATCCGCGACATGCCG 
ACCCGGATCTGGTTTTGGATCACCCCCCGCCGAAA 
R380 
CGTACTCCACCTCGCCCGCCCTTGCGGCGGACAGCACGCGCGGCTCGACGAAGCGACCGT 
CCGCATCGATCGGCGAATTGGCCTGTGCCACCACGTGGCGGTCCTCCTCGTCGGCGGTCA 
GGTACACGATCTCGTCGCTAACCACGCCGTCGACCACCTTGCGGTACGGCGTTTCGATGA 
ACCCGAACGGGTTGACCCGCGCGTACACCGACAGCGAGCCGAACAGACCGATGTTGGGCC 
CCTCAGGGGTTTCGATCGGGCACATCCGGCCGTAGTGCGACGGGTGCACGTCGCGGACCT 
CCAGCCCGGCACGCTCACGTGACAGACCGCCGGGCCCCAGCGCCGACAGTCGGCGCTTGT 
GGGTCAACCCCGACAGCGGGTTGTTCTGGTCCATGAATTGGCTCAGCTGGCTGGTGCCGA 
AGAACTCCTTGATCGCGGCGACCACCGGCCGGATGTTGATCAACGTCTGCGGTGTGATCG 
CCTCCACGTCCTGGGTGGTCATCCGCTCCCGGACCACCCGCTCCATCCGCGACATGCCGA 
CCCGGATCTGGTTTTGGATCGCTTCCCGCCGAA 
R387 
TTGTGCTCCACTCTGCGCACAGCCCTGTGCGGACCAGCACGCGCGGCTCGACGAAGCGAC 
CGTCCGCATCGATCGGCGAATTGCCTGTGCCACCACGTGGCGGTCCTCCTCGTCGGCGGT 
CAGGTACACGATCTCGTCGCTAACCACGCCGTCGACCACCTTGCGGTACGGCGTTTCGAT 
GAACCCGAACGGGTTGACCCGCGCGTACACCGACAGCGAGCCGATCAGACCGATGTTGGG 
CCCCTCAGGGGTTTCGATCGGGCACATCCGGCCGTAGTGCGACGGGTGCACGTCGCGGAC 
CTCCAGCCCGGCACGCTCACGTGACAGACCGCCGGGCCCCAGCGCCAACAGTCGGCGCTT 
GTGGGTCAACCCCGACAGCGGGTTGTTCTGGTCCATGAATTGGCTCAGCTGGCTGGTGCC 
GAAGAACTCCTTGATCGCGGCGACCACCGGCCGGATGTTGATCAACGTCTGCGGTGTGAT 
CGCCTCCACGTCCTGGGTGGTCATCCGCTCCCGGACCACCCGCTCCATCCGCGACATGCC 
GACCCGGATCTGGTTTTGGATCACCTCCCGCCGAACGTCCTTTTTTTTTTTTTTTTTTTT 
TCTCTCTTTCTTTTTTTCTTTTTCTCTACTCTCTTCCTTCTCTTCTTTTTTTTCTCCTTT 
TTTTTTTTTTCTCTTATGTGTATGGGCGTCCCCCCCTCTCCTCCTTCCCTCTCACCAACT 
TCATTCATCAAAATCACCACCATATTGCCTCTTTCATTTCTGTTGTCGCCCTCGCCCACC 
CGCGCCTCCCGCGCCCTGTCTTCTGCTGCTGCTTCTCGCTATGAG 
R389 
CGTACTCCACCTCGCCCGCCCTTGCGGCGGACCAGCACGCGCGGCTCGACGAAGCGACCG 
TCCGCATCGATCGGCGAATTGGCCTGTGCCACCACGTGGCGGTCCTCCTCGTCGGCGGTC 
AGGTACACGATCTCGTCGCTAACCACGCCGTCGACCACCTTGCGGTACGGCGTTTCGATG 
AACCCGAACGGGTTGACCCGCGCGTACACCGACAGCGAGCCGATCAGACCGATGTTGGGC 
CCCTCAGGGGTTTCGATCGGGCACATCCGGCCGTAGTGCGACGGGTGCACGTCGCGGACC 
TCCAGCCCGGCACGCTCACGTGACAGACCGCCGGGCCCCGGCGCCGACAGTCGGCGCTTG 
TGGGTCAACCCCGACAGCGGGTTGTTCTGGCCCATGAATTGGCTCAGCTGGCTGGTGCCG 
AAGAACTCCTTGATCGCGGCGACCACCGGCCGGATGTTGATCAACGTCTGCGGTGTGATC 
146 
GCCTCCACGTCCTGGGTGGTCATCCGCTCCCGGACCACCCGCTCCATCCGCGACATGCCG 
ACCCGGATCTGGTTTTGGATCACTTCTGCCCCAAA 
KLM 05240 
TCCACCGTCGCCCGCCATTAGCGTGCGGTACAGCACGCGCGGATCGACGAAGCGACCGTC 
CGCATCGATCGGCGAATTGGCCTGTGCCACCGCGTGGCGGTCCTCCTCGTCGGCGGTCAG 
GTACACGATCTCGTCGCTAACCACGCCGTCGACCACCTTGCGGTACGGCGTTTCGATGAA 
CCCGAACGGGTTGACCCGCGCGTACACCGACAGCGAGCCGATCAGACCGATGTTGGGCCC 
CTCAGGGGTTTCGATCGGGCACATCCGGCCGTAGTGCGACGGGTGCACGTCGCGGACCTC 
CAGCCCGGCACGCTCACGTGACAGACCGCCGGGCCCCAGCGCCAACAGTCGGCGCTTGTG 
GGTCAACCCCGACAGCGGGTTGTTCTGGTCCATGAATTGGCTCAGCTGGCTGGTGCCGAA 
GAACTCCTTGATCGCGGCGACCACCGGCCGGATGTTGATCAACGTCTGCGGTGTGATCGC 
CTCCACGTCCTGGGTGGTCATCCGCTCCCGGACCACCCGCTCCATCCGCGACATGCCGAC 
CCGGATCTGGTTTTGGATCAGCTCCGCCGAATTTGGGGGCCTTTCTGTTGTTTTTTTTTT 
TGTTGTTTTGGGGGTGCTGGGTGCGGCGCGGCGGCTGCGGCGCGCCCGGCGCCGACGGTT 
CGCTGGTCGTGAAACGGTGTGTTCTGCGTGTGAGCTGCCGCGGCACGCGGGTGAGCGATC 
GCCGTCGCGAGTCAGACAATGGGCCGCTTCCGATGTCGATGCAGTCGCGACTCTGCCCCA 
TGGCAGGTGCGCATGATGCAGGAGGATGATAGTCGGTGCAAATGTCACTGCGTTCCTGCG 
CATGCTAGTACTGGAACACGCACACACTCAGACGCGCTGCGCTCTGACGGTGCGCTGGGG 
AGAGGTTGTGGTGG 
MTN 053338 
CCACCGTCGCCCGCCATTGACGGCGGAACAGCACGCGCGGCTCGACGAAGCGACCGTCCG 
CATCGATCGGCGAATTGGCCTGTGCCACCACGTGGCGGTCCTCCTCGTCGGCGGTCAGGT 
ACACGATCTCGTCGCTAACCACGCCGTCGACCACCTTGCGGTACGGCGTTTCGATGAACC 
CGAACGGGTTGACCCGCGCGTACACCGACAGCGAGCCGATCAGACCGATGTTGGGCCCCT 
CAGGGGTTTCGATCGGGCACATCCGGCCGTAGTGCGACGGGTGCACGTCGCGGACCTCCA 
GCCCGGCACGCTCACGTGACAGACCGCCGGGCCCCGGCGCCGACAGTCGGCGCTTGTGGG 
TCAACCCCGACAGCGGGTTGTTCTGGTCCATGAATTGGCTCAGCTGGCTGGTGCCGAAGA 
ACTCCTTGATCGCGGCGACCACCGGCCGGATGTTGATCAACGTCTGCGGTGTGATCGCCT 
CCACGTCCTGGGTGGTCATCCGCTCCCGGACCACCCGCTCCATCCGCGACATGCCGACCC 
GGATCTGGTTTTGGATCAGCTCCCGCCGAAAGGGGGGTGCGTGGTGGCGGCTCTTTGTTT 
GTTGGCGGGTGGTGCGCGGGGGGGGTGTTTGCGCTCTCCTATTTCGCCAAGTGAAATCTG 
ACCTCGCCCCGAGACGGTGGTGTCGGCGTCGTGTCTGTGGTTGCCCCGTGTGGGGGCGCG 
GTGAGCGTCGTTGTTGGGTGTCGTGGGATGTGCTTCTGCTCTTGCTCAGGGGGCGCAAGG 
GACGCGAGCGGCGCGCCGCCGCGCTCGACGCGAGGCGGCGAGCGTGGCTGTTTTCAACTG 
CTCTCTTCTGTCGTCTTATGTGAGCGTGCGTAGCTGGGACAGCGAGCGAGATGGTTACCA 
GGCGTGAGCCCCCTGGG 
NOMI 052951 
GCTTCCGACCGTCGCCCGCCTCTGCGGCGGCACAGCACGCGCGGCTCGACAAAGCGACCG 
TCCGCATCGATCGGCGGAATTGGCCTGTGCCACCGCGTGGCGGTCCTCCTCGTCGGCGGT 
CAGGTACACGATCTCGTCGCTAACCACGCCGTCGACCACCTTGCGGTACGGCGTTTCGAT 
GAACCCGAACGGGTTGACCCGCGCGTACACCGACAGCGAGCCGATCAGACCGATGTTGGG 
CCCCTCAGGGGTTTCGATCGGGCACATCCGGCCGTAGTGCGACGGGTGCACGTCACGGAC 
CTCCAGCCCGGCACGCTCACGTGACAGACCGCCGGGCCCCAGCGCCAACAGTCGGCGCTT 
GTGGGTCAACCCCGACAGCGGGTTGTTCTGGTCCATGAATTGGCTTCAGCTGGCTGGTGC 
CAAAAGAAACTCCTTTGATCGGCGGGCGACCACCGGCCCGGTATGTTGATTCAAACGTCC 
TGCGGGTGTGATTCGCCCTTCCACCGTTCCTAGGGTGGGTCCATTCCCGCCTCCCCGGGA 
CCCACCCCGGCTTCCAATGCCGGCGTACCATTGCCCGGACCCGCGGGGATTCGTGGGTTG 
147 
TTTGGGATTCAGGCCTCCCGTCCCCGAAATCTCTCGTTCAGCGTGGGCGTTCAGCCAACG 
GGGAGGCGCTGAGCGAGGCAGACTGGAGACGTGCCTTGCAGTGCATCTATCATACGTTGA 
AGGTAGATCATGCAGAGCTACAGACGTCGGGTGCTGTGTCAGGTGATGCATGCGGCTGCC 
TCGCGCTAACTATGACATATCTAGACTGCACTGAGAGCGACAGACTCACAGCTGTAGTCA 
TGAATACCGTTCTCTGCATGCTACAACCACTTCCTGTGCATGGTTTCCCCCCACGTACTG 
GATTAACGATGGCTCCGTCCCGGGCGGGCTTTGCCCGGCCCTGGGCCCGGGGCGCGCGGC 
GCAACACCCGGTTTTTGGGGGGGGGGGGGGGCA 
RIM 052872 
CACGTCCACCGTCGCCCGCCTTAGCTGCGGTACAGCACGCGCGGCTCGACGAAGCGACCG 
TCCGCATCGATCGGCGAATTGGCCTGTGCCACCACGTGGCGGTCCTCCTCGTCGGCGGTC 
AGGTACACGATCTCGTCGCTAACCACGCCGTCGACCACCTTGCGGTACGGCGTTTCGATG 
AACCCGAACGGGTTGACCCGCGCGTACACCGACAGCGAGCCGATCAGACCGATGTTGGGC 
CCCTCAGGGGTTTCGATCGGGCACATCCGGCCGTAGTGCGACGGGTGCACGTCGCGGACC 
TCCAGCCCGGCACGCTCACGTGACAGACCGCCGGGCCCCAGCGCCAACAGTCGGCGCTTG 
TGGGTCAACCCCGACAGCGGGTTGTTCTGGTCCATGAATTGGCTCAGCTGGCTGGTGCCG 
AAGAACTCCTTGATCGCGGCGACCACCGGCCGGATGTTGATCAACGTCTGCGGTGTGATC 
GCCTCCACGTCCTGGGTGGTCATCCGCTCCCGGACCACCCGCTCCATCCGCGACATGCCG 
ACCCGGATCTGGTTTTGGATCAGCTCCAACGA CGACTTGTTTCTTTTCTCTTCCGCGCG 
GTGTTGTTTGCCCCGCTGCCGTCATACGAGAGCTCTGGCCGTTATGCTGTGTGTGCTGGG 
TGGTGTCTGTTACGGTGCTAAGTTATAAAAATACAATTCAGACAGTATACTCCTCCGCGT 
CCGGCGGGGCTGCTGATGCTGCAGTGTTGGGTGTGAGAGTGGATGTAGGGCGTGAGTGTG 
GGAGTGAAGAGTAAGCTCATATGTATATCATGACTCGCACTGCATTGAATCTGTCGCGCG 
TGCGTGCGTGCGGCTGTGTGAGCTGTCGAGACGAAGTCGAACGATGCTCGACCGTGG 
SHN 053051 
TGTTCCAGTCGTCGCCACGACACATAGCTCTGTGGACCAGCACGCGCGTGTTCGACGAAG 
CGACCGTCCGCATCGATCGGCGAATTGGCCTGTGCCACCACGTGGCGGTCCTCCTCGTCG 
GCGGTCAGGTACACGATCTCGTCGCTAACCACGCCGTCGACCACCTTGCGGTACGGCGTT 
TCGATGAACCCGAACGGGTTGACCCGCGCGTACACCGACTGCGAGCCGATCAGACCGATG 
TTGGGCCCCTCAGGGGTTTCGATCGGGCACATCCGGCCGTAGTGCGACGGGTGCACGTCG 
CGGACCTCCTGCCCGGCACGCTCACGTGACAGACCGCCGGGCCCCAGCGCCAACTGTCGG 
CGCTTGTGGGTCAACCTCGACAGCGGGTTGTTCTGGTCCATGAATCTGGCTCAACTGGCT 
GGAGCCGAAAAACTCCTTGATCGCGGTGACCACCGGTCGGATGTTGATCAACGTCTGCAG 
TGTGATCGCCTGCACCGTCCTGGGTGGTCATCCAGATATGTTTATTGATTTATGTGTTCA 
GAGGAGCCACCCCCCACCCCCTCCGGGGGGGGGGGGAGAAATCCCCTTTGCTTTTGCTTC 
CCTCTACTCCCGTGGGGAGCTTCACCGATTCCGGCGGACCCCGCAAAAGTTTTGGGGCCC 
GGAGCCCCCGCGATTCTTGGTCTTTTGGGGGGGGTAAATTCACGCCCCCATCTACCAAAA 
TCGCGTTCTGCCCCCCTCGCGCGCGGCGTGGCCGGCCGACAGACAGCTGTGGTGTGCTGC 
AGCGCGTGCACTGCGTCACGCGCGTGGGTTGCGCTGTTTAGATGATGATGGTGTGCGAGT 
GCTGGGCAGAATAGAGAATAGATGGATTCGGGTAAATGTATAGGGTGGCTGCGGGTGCTG 
AGGGGCTCGGTCTGTGGG 
148 
TBD 05128 
ATCCATCGCGTCGCCCGCCATGACTGTGCGGCACAGCACGCGCTGGCTCGACGAAGCGAC 
CGTCCGCATCGATCGGCGAATTGGCCTGTGCCACCACGTGGCGGTCCTCCTCGTCGGCGG 
TCAGGTACACGATCTCGTCGCTAACCACGCCGTCGACCACCTTGCGGTACGGCGTTTCGA 
TGAACCCGAACGGGTTGACCCGCGCGTACACCGACAGCGAGCCGATCAGACCGATGTTGG 
GCCCCTCAGGGGTTTCGATCGGGCACATCCGGCCGTAGTGCGACGGGTGCACGTCGCGGA 
CCTCCAGCCCGGCACGCTCACGTGACAGACCGCCGGGCCCCAGCGCCAATCAGTCGGCGC 
TTGTGGGTCAACCCCGACAGCGGGTTGTTCTGGTCCATGAATTGGCTCAACTGGCTGGTG 
CCGAAGAACTCCTTGATCGCGGCGACCACCGGCCGGATGTTGATCAACGTCTGCTGTGTG 
ATCGCCTCCACGTCCTGGGTGGTCATCCGCTCAAGAGACCAACCGATCCATCCGCGACAT 
GCCGACCCGGATCTGGTTTTGGATCAACTTTAAACAAATTATCCTCCCCCCCCCCCCCCC 
CCTCCCGTGCTTCCTTCTGGCCCTCTCTCTTGCTCCGACTAGAGATGGAGCTGAGACGTA 
CGCAGTCCTGTGATGCCCTCGCGGTCTGCGCATGGCTTAGGGTATCTCTAGTACTAGCCA 
TCATACTGTATAAAACTACTCTTCTCCATACTCACTCCTCTCTCCCTGCCACCGCCCCAG 
CATGCGCAGCTTCAGCTGCGCTCCCCATGCACTAGTCTCATCTTGACTGGTTCTACTGTA 
CTCTTTTTTCTGTATGTGCTATTATTGATGGATGGTCTGTGCGATGGGATGCGTGTGGGT 
CGGCGCGCCCCTTGACTGGTGGCGGGCATATATCC 
149 
